Ingredient	UNII	CAS	InChI Key
Methylprednisolone aceponate	ET54W9J4U2	86401-95-8	DALKLAYLIPSCQL-YPYQNWSCSA-N
Methylprednisolone acetate	43502P7F0P	53-36-1	PLBHSZGDDKCEHR-LFYFAGGJSA-N
Methylprednisolone sodium succinate	LEC9GKY20K	2375-03-3	FQISKWAFAHGMGT-SGJOWKDISA-M

Product Images

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Depo-Medrol	Injection, suspension	80 mg/mL	Intralesional; Intramuscular; Intrasynovial; Soft tissue	Remedy Repack	2014-09-11	Not applicable
Depo-Medrol	Injection, suspension	80 mg/mL	Intralesional; Intramuscular; Intrasynovial; Soft tissue	Dispensing Solutions, Inc.	1959-05-28	Not applicable
Depo-Medrol	Injection, suspension	40 mg/mL	Intra-articular; Intralesional; Intramuscular; Soft tissue	A S Medication Solutions	1959-05-28	2017-06-20
Depo-Medrol	Injection, suspension	40 mg/mL	Intra-articular; Intralesional; Intramuscular; Soft tissue	Remedy Repack	2017-05-10	Not applicable
Depo-Medrol	Injection, suspension	80 mg/mL	Intralesional; Intramuscular; Intrasynovial; Soft tissue	Pharmacia & Upjohn Inc	1959-05-28	Not applicable
Depo-Medrol	Injection, suspension	40 mg/mL	Intralesional; Intramuscular; Intrasynovial; Soft tissue	A S Medication Solutions	1959-05-28	2017-06-20
Depo-Medrol	Injection, suspension	40 mg/mL	Intra-articular; Intralesional; Intramuscular; Soft tissue	Pharmacia & Upjohn Inc	1959-05-28	Not applicable
Depo-Medrol	Injection, suspension	20 mg/mL	Intralesional; Intramuscular; Intrasynovial; Soft tissue	Pharmacia & Upjohn Inc	1959-05-28	Not applicable
Depo-Medrol	Injection, suspension	40 mg/mL	Intralesional; Intramuscular; Intrasynovial; Soft tissue	Rebel Distributors	1959-05-28	Not applicable
Depo-Medrol	Injection, suspension	40 mg/mL	Intra-articular; Intralesional; Intramuscular; Soft tissue	Cardinal Health	1959-05-28	Not applicable

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
A-methapred	Injection, powder, lyophilized, for solution	40 mg/mL	Intramuscular; Intravenous	Hospira, Inc.	2005-12-20	2016-10-26
A-methapred	Injection, powder, lyophilized, for solution	125 mg/2mL	Intramuscular; Intravenous	Hospira, Inc.	2005-12-20	2016-10-26
MethylPREDNISolone	Tablet	4 mg/1	Oral	Avera Mc Kennan Hospital	2015-07-10	Not applicable
Methylprednisolone	Tablet	16 mg/1	Oral	Kaiser Foundations Hospitals	2012-09-12	Not applicable
Methylprednisolone	Tablet	4 mg/1	Oral	A S Medication Solutions	2016-05-26	2017-06-20
MethylPREDNISolone	Tablet	4 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	1998-12-22	Not applicable
Methylprednisolone	Tablet	4 mg/1	Oral	Unit Dose Services	1997-10-31	Not applicable
MethylPREDNISolone	Tablet	4 mg/1	Oral	A S Medication Solutions	1998-12-22	2017-06-20
MethylPREDNISolone	Tablet	4 mg/1	Oral	Dispensing Solutions, Inc.	1998-12-22	Not applicable
Methylprednisolone	Tablet	4 mg/1	Oral	bryant ranch prepack	1997-10-31	Not applicable

Unapproved/Other Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Hybrisil	Gel	10 mg/g	Topical	Bio Zone Laboratories, Inc.	2010-05-05	Not applicable
Medroloan II SUIK	Injection, suspension	40 mg/mL	Intra-articular; Intralesional; Intramuscular; Soft tissue	Asclemed Usa, Inc.	1959-05-28	Not applicable
Medroloan SUIK	Injection, suspension	40 mg/mL	Intra-articular; Intralesional; Intramuscular; Soft tissue	Asclemed Usa, Inc.	1959-05-28	Not applicable

International/Other Brands

Medrate / Medrol / Medrone / Meprolone / Solomet / Urbason

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Depo-medrol With Lidocaine	Methylprednisolone acetate (40 mg) + Lidocaine hydrochloride (10 mg)	Solution	Intra-articular; Intrabursal	Pfizer	1973-12-31	Not applicable
Medrol Acne Lotion	Methylprednisolone acetate (2.5 mg) + Aluminum chlorohydrate (100 mg) + Sulfur (50 mg)	Lotion	Topical	Pfizer	1973-12-31	2014-04-04
Methylprednisolone Sodium Succinate for Injection, USP	Methylprednisolone (500 mg) + Water (10 ml)	Powder, for solution	Intramuscular; Intravenous	Hospira, Inc.	1998-03-12	Not applicable
Methylprednisolone Sodium Succinate for Injection, USP	Methylprednisolone (1 g) + Water (20 ml)	Powder, for solution	Intramuscular; Intravenous	Hospira, Inc.	1998-03-12	Not applicable
Neo-medrol	Methylprednisolone acetate (2.5 mg) + Neomycin sulfate (5 mg)	Cream	Topical	Pfizer	1960-12-31	2006-08-02
Neo-medrol Acne Lotion	Methylprednisolone acetate (2.5 mg) + Aluminum chlorohydrate (100 mg) + Neomycin sulfate (2.5 mg) + Sulfur (50 mg)	Lotion	Topical	Pfizer	1965-12-31	Not applicable
Physicians EZ Use M-pred	Methylprednisolone acetate + Bupivacaine hydrochloride + Povidone-iodine	Kit		Proficient Rx LP	2013-05-30	Not applicable
Physicians EZ Use M-pred	Methylprednisolone acetate + Bupivacaine hydrochloride + Povidone-iodine	Kit	Epidural; Infiltration; Intramuscular; Intrasynovial; Soft tissue; Topical	Asclemed Usa, Inc.	2013-05-30	Not applicable
ReadySharp Anesthetics plus MethylPrednisolone 80	Methylprednisolone acetate + Bupivacaine hydrochloride + Lidocaine hydrochloride	Kit	Epidural; Infiltration; Intra-articular; Intralesional; Intramuscular; Soft tissue	Terrain Pharmaceuticals	2015-12-29	Not applicable
ReadySharp-P40	Methylprednisolone acetate + Bupivacaine hydrochloride + Lidocaine hydrochloride	Kit	Epidural; Infiltration; Intra-articular; Intralesional; Intramuscular; Soft tissue	Terrain Pharmaceuticals	2015-12-29	Not applicable

Categories

UNII

X4W7ZR7023

CAS number

83-43-2

Weight

Average: 374.4706
Monoisotopic: 374.20932407

Chemical Formula

C₂₂H₃₀O₅

InChI Key

VHRSUDSXCMQTMA-PJHHCJLFSA-N

InChI

InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1

IUPAC Name

(1S,2R,8S,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,8,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one

SMILES

[H][[email protected]@]12CC[[email protected]](O)(C(=O)CO)[[email protected]@]1(C)C[[email protected]](O)[[email protected]@]1([H])[[email protected]@]2([H])C[[email protected]](C)C2=CC(=O)C=C[[email protected]]12C

Pharmacology

Indication

Adjunctive therapy for short-term administration in rheumatoid arthritis.

Structured Indications

Pharmacodynamics

Methylprednisolone and its derivatives, methylprednisolone sodium succinate and methylprednisolone acetate, are synthetic glucocorticoids used as antiinflammatory or immunosuppressive agents.

Mechanism of action

Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.

Target	Actions	Organism
AGlucocorticoid receptor	agonist	Human

Absorption

Oral bioavailability 80-99%

Volume of distribution

Not Available

Protein binding

78%

Metabolism

Hepatic

Route of elimination

Not Available

Half life

1-3 hours

Clearance

Not Available

Toxicity

LD₅₀=2000 mg/kg (orally in rat)

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
1,10-Phenanthroline	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with 1,10-Phenanthroline.	Experimental
2,4-thiazolidinedione	The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Methylprednisolone.	Investigational
Acarbose	The therapeutic efficacy of Acarbose can be decreased when used in combination with Methylprednisolone.	Approved, Investigational
Aceclofenac	The risk or severity of adverse effects can be increased when Aceclofenac is combined with Methylprednisolone.	Approved
Acemetacin	The risk or severity of adverse effects can be increased when Acemetacin is combined with Methylprednisolone.	Approved
Acetaminophen	The serum concentration of Methylprednisolone can be increased when it is combined with Acetaminophen.	Approved
Acetohexamide	The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Methylprednisolone.	Withdrawn
Acetyldigitoxin	Acetyldigitoxin may decrease the cardiotoxic activities of Methylprednisolone.	Approved
Acetyldigoxin	Acetyldigoxin may decrease the cardiotoxic activities of Methylprednisolone.	Experimental
Acetylsalicylic acid	The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Methylprednisolone.	Approved, Vet Approved
Adapalene	The risk or severity of adverse effects can be increased when Adapalene is combined with Methylprednisolone.	Approved
Afatinib	The serum concentration of Methylprednisolone can be increased when it is combined with Afatinib.	Approved
AICA ribonucleotide	The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Methylprednisolone.	Experimental
Albendazole	The serum concentration of Methylprednisolone can be increased when it is combined with Albendazole.	Approved, Vet Approved
Alclofenac	The risk or severity of adverse effects can be increased when Alclofenac is combined with Methylprednisolone.	Approved, Withdrawn
Aldesleukin	Methylprednisolone may decrease the antineoplastic activities of Aldesleukin.	Approved
Aldosterone	The serum concentration of Methylprednisolone can be decreased when it is combined with Aldosterone.	Experimental
Alectinib	The serum concentration of Methylprednisolone can be increased when it is combined with Alectinib.	Approved
Alfentanil	The serum concentration of Methylprednisolone can be increased when it is combined with Alfentanil.	Approved, Illicit
Algeldrate	The bioavailability of Methylprednisolone can be decreased when combined with Algeldrate.	Experimental
Allicin	The therapeutic efficacy of Allicin can be decreased when used in combination with Methylprednisolone.	Investigational
Almagate	The bioavailability of Methylprednisolone can be decreased when combined with Almagate.	Experimental
Almasilate	The bioavailability of Methylprednisolone can be decreased when combined with Almasilate.	Experimental
Alminoprofen	The risk or severity of adverse effects can be increased when Alminoprofen is combined with Methylprednisolone.	Experimental
Alogliptin	The therapeutic efficacy of Alogliptin can be decreased when used in combination with Methylprednisolone.	Approved
Aloglutamol	The bioavailability of Methylprednisolone can be decreased when combined with Aloglutamol.	Experimental
Aloxiprin	The risk or severity of adverse effects can be increased when Aloxiprin is combined with Methylprednisolone.	Experimental
Aluminium	The bioavailability of Methylprednisolone can be decreased when combined with Aluminium.	Approved
Aluminium acetoacetate	The bioavailability of Methylprednisolone can be decreased when combined with Aluminium acetoacetate.	Experimental
Aluminium glycinate	The bioavailability of Methylprednisolone can be decreased when combined with Aluminium glycinate.	Experimental
Aluminum hydroxide	The bioavailability of Methylprednisolone can be decreased when combined with Aluminum hydroxide.	Approved
Amantadine	The serum concentration of Methylprednisolone can be increased when it is combined with Amantadine.	Approved
Ambenonium	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ambenonium.	Approved
Aminohippuric acid	The serum concentration of Methylprednisolone can be increased when it is combined with Aminohippuric acid.	Approved
Aminosalicylic Acid	The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Methylprednisolone.	Approved
Amiodarone	The serum concentration of Methylprednisolone can be increased when it is combined with Amiodarone.	Approved, Investigational
Amitriptyline	The serum concentration of Methylprednisolone can be increased when it is combined with Amitriptyline.	Approved
Amlodipine	The serum concentration of Methylprednisolone can be increased when it is combined with Amlodipine.	Approved
Amphotericin B	Methylprednisolone may increase the hypokalemic activities of Amphotericin B.	Approved, Investigational
Amprenavir	The serum concentration of Methylprednisolone can be decreased when it is combined with Amprenavir.	Approved
Amsacrine	The serum concentration of Methylprednisolone can be increased when it is combined with Amsacrine.	Approved
Andrographolide	The risk or severity of adverse effects can be increased when Andrographolide is combined with Methylprednisolone.	Investigational
Anisodamine	The risk or severity of adverse effects can be increased when Anisodamine is combined with Methylprednisolone.	Investigational
Antipyrine	The risk or severity of adverse effects can be increased when Antipyrine is combined with Methylprednisolone.	Approved
Apocynin	The risk or severity of adverse effects can be increased when Apocynin is combined with Methylprednisolone.	Investigational
Apremilast	The risk or severity of adverse effects can be increased when Apremilast is combined with Methylprednisolone.	Approved, Investigational
Aprepitant	The serum concentration of Methylprednisolone can be increased when it is combined with Aprepitant.	Approved, Investigational
Astemizole	The serum concentration of Methylprednisolone can be increased when it is combined with Astemizole.	Approved, Withdrawn
Atazanavir	The serum concentration of Methylprednisolone can be increased when it is combined with Atazanavir.	Approved, Investigational
Atenolol	The serum concentration of Methylprednisolone can be increased when it is combined with Atenolol.	Approved
Atomoxetine	The metabolism of Methylprednisolone can be decreased when combined with Atomoxetine.	Approved
Atorvastatin	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Atorvastatin.	Approved
Atracurium besylate	Atracurium besylate may increase the adverse neuromuscular activities of Methylprednisolone.	Approved
Azapropazone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Methylprednisolone.	Withdrawn
Azelastine	The serum concentration of Methylprednisolone can be increased when it is combined with Azelastine.	Approved
Azithromycin	The serum concentration of Methylprednisolone can be increased when it is combined with Azithromycin.	Approved
Balaglitazone	The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Methylprednisolone.	Investigational
Balsalazide	The risk or severity of adverse effects can be increased when Balsalazide is combined with Methylprednisolone.	Approved, Investigational
BCG vaccine	The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Methylprednisolone.	Investigational
Bempedoic acid	The therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Methylprednisolone.	Investigational
Bendazac	The risk or severity of adverse effects can be increased when Bendazac is combined with Methylprednisolone.	Experimental
Bendroflumethiazide	Methylprednisolone may increase the hypokalemic activities of Bendroflumethiazide.	Approved
Benorilate	The risk or severity of adverse effects can be increased when Benorilate is combined with Methylprednisolone.	Experimental
Benoxaprofen	The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Methylprednisolone.	Withdrawn
Benzocaine	The serum concentration of Methylprednisolone can be increased when it is combined with Benzocaine.	Approved
Benzoic Acid	The therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Methylprednisolone.	Approved
Bepridil	The serum concentration of Methylprednisolone can be increased when it is combined with Bepridil.	Approved, Withdrawn
Bevacizumab	Bevacizumab may increase the cardiotoxic activities of Methylprednisolone.	Approved, Investigational
Bevonium	The risk or severity of adverse effects can be increased when Bevonium is combined with Methylprednisolone.	Experimental
Biperiden	The serum concentration of Methylprednisolone can be increased when it is combined with Biperiden.	Approved
Bismuth Subcitrate	The bioavailability of Methylprednisolone can be decreased when combined with Bismuth Subcitrate.	Approved
Bismuth subnitrate	The bioavailability of Methylprednisolone can be decreased when combined with Bismuth subnitrate.	Experimental
Boceprevir	The serum concentration of Methylprednisolone can be increased when it is combined with Boceprevir.	Withdrawn
Bortezomib	The metabolism of Methylprednisolone can be decreased when combined with Bortezomib.	Approved, Investigational
Bosentan	The serum concentration of Methylprednisolone can be decreased when it is combined with Bosentan.	Approved, Investigational
Bosutinib	The serum concentration of Methylprednisolone can be increased when it is combined with Bosutinib.	Approved
Bromfenac	The risk or severity of adverse effects can be increased when Bromfenac is combined with Methylprednisolone.	Approved
Bromocriptine	The serum concentration of Methylprednisolone can be increased when it is combined with Bromocriptine.	Approved, Investigational
Bucillamine	The risk or severity of adverse effects can be increased when Bucillamine is combined with Methylprednisolone.	Investigational
Bufexamac	The risk or severity of adverse effects can be increased when Bufexamac is combined with Methylprednisolone.	Experimental
Buformin	The therapeutic efficacy of Buformin can be decreased when used in combination with Methylprednisolone.	Withdrawn
Bumadizone	The risk or severity of adverse effects can be increased when Bumadizone is combined with Methylprednisolone.	Experimental
Bumetanide	Methylprednisolone may increase the hypokalemic activities of Bumetanide.	Approved
Buprenorphine	The serum concentration of Methylprednisolone can be increased when it is combined with Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buspirone	The serum concentration of Methylprednisolone can be increased when it is combined with Buspirone.	Approved, Investigational
Cabazitaxel	The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Methylprednisolone.	Approved
Cabergoline	The risk or severity of adverse effects can be increased when Cabergoline is combined with Methylprednisolone.	Approved
Caffeine	The serum concentration of Methylprednisolone can be increased when it is combined with Caffeine.	Approved
Calcitriol	The therapeutic efficacy of Calcitriol can be decreased when used in combination with Methylprednisolone.	Approved, Nutraceutical
Calcium Carbonate	The bioavailability of Methylprednisolone can be decreased when combined with Calcium Carbonate.	Approved
Calcium silicate	The bioavailability of Methylprednisolone can be decreased when combined with Calcium silicate.	Experimental
Canagliflozin	The serum concentration of Methylprednisolone can be increased when it is combined with Canagliflozin.	Approved
Candesartan cilexetil	The serum concentration of Methylprednisolone can be increased when it is combined with Candesartan.	Approved
Capromab pendetide	Methylprednisolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.	Approved
Captopril	The serum concentration of Methylprednisolone can be increased when it is combined with Captopril.	Approved
Carbamazepine	The serum concentration of Methylprednisolone can be decreased when it is combined with Carbamazepine.	Approved, Investigational
Carbaspirin calcium	The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Methylprednisolone.	Experimental
Carbutamide	The therapeutic efficacy of Carbutamide can be decreased when used in combination with Methylprednisolone.	Experimental
Carprofen	The risk or severity of adverse effects can be increased when Carprofen is combined with Methylprednisolone.	Approved, Vet Approved, Withdrawn
Carvedilol	The serum concentration of Methylprednisolone can be increased when it is combined with Carvedilol.	Approved, Investigational
Caspofungin	The serum concentration of Methylprednisolone can be increased when it is combined with Caspofungin.	Approved
Castanospermine	The therapeutic efficacy of Castanospermine can be decreased when used in combination with Methylprednisolone.	Experimental
Celecoxib	The risk or severity of adverse effects can be increased when Celecoxib is combined with Methylprednisolone.	Approved, Investigational
Ceritinib	The serum concentration of Methylprednisolone can be increased when it is combined with Ceritinib.	Approved
Cerivastatin	The serum concentration of Cerivastatin can be increased when it is combined with Methylprednisolone.	Withdrawn
Chloroquine	The serum concentration of Methylprednisolone can be increased when it is combined with Chloroquine.	Approved, Vet Approved
Chlorothiazide	Methylprednisolone may increase the hypokalemic activities of Chlorothiazide.	Approved, Vet Approved
Chlorotrianisene	The serum concentration of Methylprednisolone can be increased when it is combined with Chlorotrianisene.	Withdrawn
Chlorpromazine	The serum concentration of Methylprednisolone can be increased when it is combined with Chlorpromazine.	Approved, Vet Approved
Chlorpropamide	The serum concentration of Methylprednisolone can be increased when it is combined with Chlorpropamide.	Approved
Chlorprothixene	The serum concentration of Methylprednisolone can be increased when it is combined with Chlorprothixene.	Approved, Withdrawn
Chlorthalidone	Methylprednisolone may increase the hypokalemic activities of Chlorthalidone.	Approved
Cholesterol	The serum concentration of Methylprednisolone can be increased when it is combined with Cholesterol.	Experimental
Cholestyramine	Cholestyramine can cause a decrease in the absorption of Methylprednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Cholic Acid	The serum concentration of Methylprednisolone can be decreased when it is combined with Cholic Acid.	Approved
Choline magnesium trisalicylate	The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Methylprednisolone.	Approved
Ciglitazone	The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Methylprednisolone.	Experimental
Cilazapril	The serum concentration of Methylprednisolone can be increased when it is combined with Cilazapril.	Approved
Cimetidine	The serum concentration of Methylprednisolone can be decreased when it is combined with Cimetidine.	Approved
Cinoxacin	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Cinoxacin.	Approved, Withdrawn
Ciprofloxacin	The serum concentration of Methylprednisolone can be increased when it is combined with Ciprofloxacin.	Approved, Investigational
Citalopram	The serum concentration of Methylprednisolone can be increased when it is combined with Citalopram.	Approved
Clarithromycin	The serum concentration of Methylprednisolone can be increased when it is combined with Clarithromycin.	Approved
Clemastine	The metabolism of Methylprednisolone can be decreased when combined with Clemastine.	Approved
Clofazimine	The serum concentration of Methylprednisolone can be increased when it is combined with Clofazimine.	Approved, Investigational
Clomipramine	The serum concentration of Methylprednisolone can be increased when it is combined with Clomipramine.	Approved, Vet Approved
Clonixin	The risk or severity of adverse effects can be increased when Clonixin is combined with Methylprednisolone.	Approved
Clotrimazole	The metabolism of Methylprednisolone can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Cobicistat	The serum concentration of Methylprednisolone can be increased when it is combined with Cobicistat.	Approved
Colchicine	The serum concentration of Methylprednisolone can be increased when it is combined with Colchicine.	Approved
Colesevelam	Colesevelam can cause a decrease in the absorption of Methylprednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Colestipol	Colestipol can cause a decrease in the absorption of Methylprednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Colforsin	The serum concentration of Methylprednisolone can be increased when it is combined with Colforsin.	Experimental
Conivaptan	The serum concentration of Methylprednisolone can be increased when it is combined with Conivaptan.	Approved, Investigational
Conjugated estrogens	The serum concentration of Methylprednisolone can be increased when it is combined with Conjugated estrogens.	Approved
Corticorelin ovine triflutate	The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Methylprednisolone.	Approved
Coumaphos	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Coumaphos.	Vet Approved
Crizotinib	The metabolism of Methylprednisolone can be decreased when combined with Crizotinib.	Approved
Curcumin	The risk or severity of adverse effects can be increased when Curcumin is combined with Methylprednisolone.	Investigational
Cyclopenthiazide	Methylprednisolone may increase the hypokalemic activities of Cyclopenthiazide.	Experimental
Cyclophosphamide	Cyclophosphamide may increase the cardiotoxic activities of Methylprednisolone.	Approved, Investigational
Cyclosporine	The serum concentration of Methylprednisolone can be increased when it is combined with Cyclosporine.	Approved, Investigational, Vet Approved
Cymarin	Cymarin may decrease the cardiotoxic activities of Methylprednisolone.	Experimental
D-Limonene	The risk or severity of adverse effects can be increased when D-Limonene is combined with Methylprednisolone.	Investigational
Dabrafenib	The serum concentration of Methylprednisolone can be decreased when it is combined with Dabrafenib.	Approved
Daclatasvir	The serum concentration of Methylprednisolone can be increased when it is combined with Daclatasvir.	Approved
Dactinomycin	The serum concentration of Methylprednisolone can be increased when it is combined with Dactinomycin.	Approved
Daidzein	The serum concentration of Methylprednisolone can be increased when it is combined with Daidzein.	Experimental
Darunavir	The serum concentration of Methylprednisolone can be increased when it is combined with Darunavir.	Approved
Dasatinib	The serum concentration of Methylprednisolone can be increased when it is combined with Dasatinib.	Approved, Investigational
Daunorubicin	The serum concentration of Methylprednisolone can be decreased when it is combined with Daunorubicin.	Approved
Decamethonium	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Decamethonium.	Approved
Deferasirox	The serum concentration of Methylprednisolone can be decreased when it is combined with Deferasirox.	Approved, Investigational
Delavirdine	The metabolism of Methylprednisolone can be decreased when combined with Delavirdine.	Approved
Demecarium	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Demecarium.	Approved
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Methylprednisolone.	Approved
Deoxyspergualin	The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Methylprednisolone.	Investigational
dersalazine	The risk or severity of adverse effects can be increased when dersalazine is combined with Methylprednisolone.	Investigational
Desipramine	The serum concentration of Methylprednisolone can be increased when it is combined with Desipramine.	Approved
Deslanoside	Deslanoside may decrease the cardiotoxic activities of Methylprednisolone.	Approved
Desloratadine	The serum concentration of Methylprednisolone can be increased when it is combined with Desloratadine.	Approved, Investigational
Dexamethasone	The serum concentration of Methylprednisolone can be decreased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dextromethorphan	The serum concentration of Methylprednisolone can be increased when it is combined with Dextromethorphan.	Approved
Dichlorvos	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Dichlorvos.	Vet Approved
Diclofenac	The serum concentration of Methylprednisolone can be increased when it is combined with Diclofenac.	Approved, Vet Approved
Dienestrol	The serum concentration of Methylprednisolone can be increased when it is combined with Dienestrol.	Approved
Diethylstilbestrol	The serum concentration of Methylprednisolone can be increased when it is combined with Diethylstilbestrol.	Approved
Difenpiramide	The risk or severity of adverse effects can be increased when Difenpiramide is combined with Methylprednisolone.	Experimental
Diflunisal	The risk or severity of adverse effects can be increased when Diflunisal is combined with Methylprednisolone.	Approved
Digitoxin	Digitoxin may decrease the cardiotoxic activities of Methylprednisolone.	Approved
Digoxin	Digoxin may decrease the cardiotoxic activities of Methylprednisolone.	Approved
Dihydroergocornine	The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Methylprednisolone.	Approved
Dihydroergocristine	The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Methylprednisolone.	Experimental
Dihydroergocryptine	The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Methylprednisolone.	Experimental
Dihydroergotamine	The metabolism of Methylprednisolone can be decreased when combined with Dihydroergotamine.	Approved
Dihydrotestosterone	Methylprednisolone may increase the fluid retaining activities of Dihydrotestosterone.	Illicit
Diltiazem	The metabolism of Methylprednisolone can be decreased when combined with Diltiazem.	Approved
Dipyridamole	The serum concentration of Methylprednisolone can be increased when it is combined with Dipyridamole.	Approved
Distigmine	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Distigmine.	Experimental
Docetaxel	The risk or severity of adverse effects can be increased when Docetaxel is combined with Methylprednisolone.	Approved, Investigational
Donepezil	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Donepezil.	Approved
Doxazosin	The serum concentration of Methylprednisolone can be increased when it is combined with Doxazosin.	Approved
Doxepin	The serum concentration of Methylprednisolone can be increased when it is combined with Doxepin.	Approved
Doxorubicin	The serum concentration of Methylprednisolone can be decreased when it is combined with Doxorubicin.	Approved, Investigational
Doxycycline	The metabolism of Methylprednisolone can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Dronabinol	The serum concentration of Methylprednisolone can be increased when it is combined with Dronabinol.	Approved, Illicit
Dronedarone	The metabolism of Methylprednisolone can be decreased when combined with Dronedarone.	Approved
Droxicam	The risk or severity of adverse effects can be increased when Droxicam is combined with Methylprednisolone.	Approved
Dulaglutide	The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Methylprednisolone.	Approved
Duvelisib	The risk or severity of adverse effects can be increased when Duvelisib is combined with Methylprednisolone.	Investigational
E-6201	The risk or severity of adverse effects can be increased when E-6201 is combined with Methylprednisolone.	Investigational
Echothiophate	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Echothiophate.	Approved
Edrophonium	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Edrophonium.	Approved
Elbasvir	The serum concentration of Methylprednisolone can be increased when it is combined with Elbasvir.	Approved
Empagliflozin	The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Methylprednisolone.	Approved
Enalapril	The serum concentration of Methylprednisolone can be increased when it is combined with Enalapril.	Approved, Vet Approved
Enasidenib	The serum concentration of Methylprednisolone can be increased when it is combined with Enasidenib.	Approved
Enoxacin	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Enoxacin.	Approved
Enzalutamide	The serum concentration of Methylprednisolone can be decreased when it is combined with Enzalutamide.	Approved
Epimestrol	The serum concentration of Methylprednisolone can be increased when it is combined with Epimestrol.	Experimental
Epirizole	The risk or severity of adverse effects can be increased when Epirizole is combined with Methylprednisolone.	Approved
Equol	The serum concentration of Methylprednisolone can be increased when it is combined with Equol.	Investigational
Ergonovine	The serum concentration of Methylprednisolone can be increased when it is combined with Ergonovine.	Approved
Ergotamine	The serum concentration of Methylprednisolone can be increased when it is combined with Ergotamine.	Approved
Erythromycin	The metabolism of Methylprednisolone can be decreased when combined with Erythromycin.	Approved, Vet Approved
Estradiol	The serum concentration of Methylprednisolone can be increased when it is combined with Estradiol.	Approved, Investigational, Vet Approved
Estramustine	The serum concentration of Methylprednisolone can be increased when it is combined with Estramustine.	Approved
Estriol	The serum concentration of Methylprednisolone can be increased when it is combined with Estriol.	Approved, Vet Approved
Estrone	The serum concentration of Methylprednisolone can be increased when it is combined with Estrone.	Approved
Etacrynic acid	Methylprednisolone may increase the hypokalemic activities of Etacrynic acid.	Approved
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Methylprednisolone.	Approved, Investigational
Ethenzamide	The risk or severity of adverse effects can be increased when Ethenzamide is combined with Methylprednisolone.	Experimental
Ethinyl Estradiol	The serum concentration of Methylprednisolone can be increased when it is combined with Ethinyl Estradiol.	Approved
Etodolac	The risk or severity of adverse effects can be increased when Etodolac is combined with Methylprednisolone.	Approved, Investigational, Vet Approved
Etofenamate	The risk or severity of adverse effects can be increased when Etofenamate is combined with Methylprednisolone.	Approved
Etoposide	The serum concentration of Methylprednisolone can be increased when it is combined with Etoposide.	Approved
Etoricoxib	The risk or severity of adverse effects can be increased when Etoricoxib is combined with Methylprednisolone.	Approved, Investigational
Etravirine	The serum concentration of Methylprednisolone can be increased when it is combined with Etravirine.	Approved
Evening primrose oil	The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Methylprednisolone.	Approved
Exenatide	The therapeutic efficacy of Exenatide can be decreased when used in combination with Methylprednisolone.	Approved, Investigational
exisulind	The risk or severity of adverse effects can be increased when exisulind is combined with Methylprednisolone.	Investigational
Felbinac	The risk or severity of adverse effects can be increased when Felbinac is combined with Methylprednisolone.	Experimental
Felodipine	The serum concentration of Methylprednisolone can be increased when it is combined with Felodipine.	Approved, Investigational
Fenbufen	The risk or severity of adverse effects can be increased when Fenbufen is combined with Methylprednisolone.	Approved
Fenoprofen	The risk or severity of adverse effects can be increased when Fenoprofen is combined with Methylprednisolone.	Approved
Fentanyl	The serum concentration of Methylprednisolone can be increased when it is combined with Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Fenthion	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Fenthion.	Vet Approved
Fentiazac	The risk or severity of adverse effects can be increased when Fentiazac is combined with Methylprednisolone.	Experimental
Feprazone	The risk or severity of adverse effects can be increased when Feprazone is combined with Methylprednisolone.	Experimental
Ferulic acid	The risk or severity of adverse effects can be increased when Ferulic acid is combined with Methylprednisolone.	Experimental
Fexofenadine	The serum concentration of Methylprednisolone can be increased when it is combined with Fexofenadine.	Approved
Fidaxomicin	The serum concentration of Methylprednisolone can be increased when it is combined with Fidaxomicin.	Approved
Fingolimod	Methylprednisolone may increase the immunosuppressive activities of Fingolimod.	Approved, Investigational
Fleroxacin	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Fleroxacin.	Approved
Floctafenine	The risk or severity of adverse effects can be increased when Floctafenine is combined with Methylprednisolone.	Approved, Withdrawn
Fluconazole	The metabolism of Methylprednisolone can be decreased when combined with Fluconazole.	Approved
Flumequine	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Flumequine.	Withdrawn
Flunixin	The risk or severity of adverse effects can be increased when Flunixin is combined with Methylprednisolone.	Vet Approved
Flunoxaprofen	The risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Methylprednisolone.	Experimental
Fluoxetine	The serum concentration of Methylprednisolone can be increased when it is combined with Fluoxetine.	Approved, Vet Approved
Fluoxymesterone	Methylprednisolone may increase the fluid retaining activities of Fluoxymesterone.	Approved, Illicit
Flupentixol	The serum concentration of Methylprednisolone can be increased when it is combined with Flupentixol.	Approved, Withdrawn
Fluphenazine	The serum concentration of Methylprednisolone can be increased when it is combined with Fluphenazine.	Approved
Flurazepam	The serum concentration of Methylprednisolone can be increased when it is combined with Flurazepam.	Approved, Illicit
Flurbiprofen	The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Methylprednisolone.	Approved, Investigational
Fluvastatin	The serum concentration of Fluvastatin can be increased when it is combined with Methylprednisolone.	Approved
Fluvoxamine	The metabolism of Methylprednisolone can be decreased when combined with Fluvoxamine.	Approved, Investigational
Fosamprenavir	The metabolism of Methylprednisolone can be decreased when combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Methylprednisolone can be increased when it is combined with Fosaprepitant.	Approved
Fosphenytoin	The serum concentration of Methylprednisolone can be decreased when it is combined with Fosphenytoin.	Approved
Furosemide	Methylprednisolone may increase the hypokalemic activities of Furosemide.	Approved, Vet Approved
Fusidic Acid	The serum concentration of Methylprednisolone can be increased when it is combined with Fusidic Acid.	Approved
Galantamine	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Galantamine.	Approved
Gallamine Triethiodide	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Gallamine Triethiodide.	Approved
Garenoxacin	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Garenoxacin.	Investigational
Gatifloxacin	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Gatifloxacin.	Approved, Investigational
Gefitinib	The serum concentration of Methylprednisolone can be increased when it is combined with Gefitinib.	Approved, Investigational
Gemifloxacin	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Gemifloxacin.	Approved, Investigational
Genistein	The serum concentration of Methylprednisolone can be increased when it is combined with Genistein.	Investigational
Ginkgo biloba	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ginkgo biloba.	Approved, Nutraceutical
Gitoformate	Gitoformate may decrease the cardiotoxic activities of Methylprednisolone.	Experimental
Glecaprevir	The serum concentration of Methylprednisolone can be increased when it is combined with Glecaprevir.	Approved
Glibornuride	The therapeutic efficacy of Glibornuride can be decreased when used in combination with Methylprednisolone.	Withdrawn
Gliclazide	The therapeutic efficacy of Gliclazide can be decreased when used in combination with Methylprednisolone.	Approved
Glimepiride	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Methylprednisolone.	Approved
Glipizide	The therapeutic efficacy of Glipizide can be decreased when used in combination with Methylprednisolone.	Approved
Gliquidone	The therapeutic efficacy of Gliquidone can be decreased when used in combination with Methylprednisolone.	Approved
GLPG-0492	Methylprednisolone may increase the fluid retaining activities of GLPG-0492.	Investigational
Glyburide	The serum concentration of Methylprednisolone can be increased when it is combined with Glyburide.	Approved
Glycerin	The serum concentration of Methylprednisolone can be increased when it is combined with Glycerin.	Approved, Investigational
Glycerol Phenylbutyrate	The therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Methylprednisolone.	Approved
Gramicidin D	The serum concentration of Methylprednisolone can be increased when it is combined with Gramicidin D.	Approved
Grepafloxacin	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Grepafloxacin.	Withdrawn
Guacetisal	The risk or severity of adverse effects can be increased when Guacetisal is combined with Methylprednisolone.	Experimental
Gusperimus	The therapeutic efficacy of Gusperimus can be decreased when used in combination with Methylprednisolone.	Investigational
Haloperidol	The serum concentration of Methylprednisolone can be increased when it is combined with Haloperidol.	Approved
Hemoglobin crosfumaril	The risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Methylprednisolone.	Experimental
Hexestrol	The serum concentration of Methylprednisolone can be increased when it is combined with Hexestrol.	Withdrawn
Higenamine	The risk or severity of adverse effects can be increased when Higenamine is combined with Methylprednisolone.	Investigational
Huperzine A	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Huperzine A.	Investigational
Hyaluronidase	The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methylprednisolone.	Approved, Investigational
Hydrochlorothiazide	Methylprednisolone may increase the hypokalemic activities of Hydrochlorothiazide.	Approved, Vet Approved
Hydrocortisone	The serum concentration of Methylprednisolone can be increased when it is combined with Hydrocortisone.	Approved, Vet Approved
Hydroflumethiazide	Methylprednisolone may increase the hypokalemic activities of Hydroflumethiazide.	Approved
Hydrotalcite	The bioavailability of Methylprednisolone can be decreased when combined with Hydrotalcite.	Experimental
Ibuprofen	The risk or severity of adverse effects can be increased when Ibuprofen is combined with Methylprednisolone.	Approved
Ibuproxam	The risk or severity of adverse effects can be increased when Ibuproxam is combined with Methylprednisolone.	Withdrawn
Icatibant	The risk or severity of adverse effects can be increased when Icatibant is combined with Methylprednisolone.	Approved
Imatinib	The metabolism of Methylprednisolone can be decreased when combined with Imatinib.	Approved
Imidazole salicylate	The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Methylprednisolone.	Experimental
Imipramine	The serum concentration of Methylprednisolone can be increased when it is combined with Imipramine.	Approved
Indacaterol	Indacaterol may increase the hypokalemic activities of Methylprednisolone.	Approved
Indapamide	Methylprednisolone may increase the hypokalemic activities of Indapamide.	Approved
Indinavir	The serum concentration of Methylprednisolone can be increased when it is combined with Indinavir.	Approved
Indobufen	The risk or severity of adverse effects can be increased when Indobufen is combined with Methylprednisolone.	Investigational
Indomethacin	The serum concentration of Methylprednisolone can be increased when it is combined with Indomethacin.	Approved, Investigational
Indoprofen	The risk or severity of adverse effects can be increased when Indoprofen is combined with Methylprednisolone.	Withdrawn
Insulin Aspart	The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Methylprednisolone.	Approved
Insulin Detemir	The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Methylprednisolone.	Approved
Insulin Glargine	The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Methylprednisolone.	Approved
Insulin Glulisine	The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Methylprednisolone.	Approved
Insulin Human	The therapeutic efficacy of Insulin Human can be decreased when used in combination with Methylprednisolone.	Approved, Investigational
Insulin Lispro	The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Methylprednisolone.	Approved
Insulin Pork	The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Methylprednisolone.	Approved
Ipidacrine	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ipidacrine.	Experimental
Isavuconazonium	The metabolism of Methylprednisolone can be decreased when combined with Isavuconazonium.	Approved, Investigational
Isoflurophate	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Isoflurophate.	Approved, Withdrawn
Isoniazid	The serum concentration of Isoniazid can be decreased when it is combined with Methylprednisolone.	Approved
Isoxicam	The risk or severity of adverse effects can be increased when Isoxicam is combined with Methylprednisolone.	Withdrawn
Isradipine	The metabolism of Methylprednisolone can be decreased when combined with Isradipine.	Approved
Itraconazole	The serum concentration of Methylprednisolone can be increased when it is combined with Itraconazole.	Approved, Investigational
Ivacaftor	The serum concentration of Methylprednisolone can be increased when it is combined with Ivacaftor.	Approved
Ivermectin	The serum concentration of Methylprednisolone can be increased when it is combined with Ivermectin.	Approved, Vet Approved
Kebuzone	The risk or severity of adverse effects can be increased when Kebuzone is combined with Methylprednisolone.	Experimental
Ketamine	The serum concentration of Methylprednisolone can be increased when it is combined with Ketamine.	Approved, Vet Approved
Ketoconazole	The serum concentration of Methylprednisolone can be increased when it is combined with Ketoconazole.	Approved, Investigational
Ketoprofen	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Methylprednisolone.	Approved, Vet Approved
Ketorolac	The risk or severity of adverse effects can be increased when Ketorolac is combined with Methylprednisolone.	Approved
Lanatoside C	Lanatoside C may decrease the cardiotoxic activities of Methylprednisolone.	Experimental
Lansoprazole	The serum concentration of Methylprednisolone can be increased when it is combined with Lansoprazole.	Approved, Investigational
Lapatinib	The serum concentration of Methylprednisolone can be increased when it is combined with Lapatinib.	Approved, Investigational
Leflunomide	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Leflunomide.	Approved, Investigational
Levofloxacin	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Levofloxacin.	Approved, Investigational
Levothyroxine	The serum concentration of Methylprednisolone can be decreased when it is combined with Levothyroxine.	Approved
Lidocaine	The serum concentration of Methylprednisolone can be increased when it is combined with Lidocaine.	Approved, Vet Approved
Linagliptin	The therapeutic efficacy of Linagliptin can be decreased when used in combination with Methylprednisolone.	Approved
Liothyronine	The serum concentration of Methylprednisolone can be decreased when it is combined with Liothyronine.	Approved, Vet Approved
Liotrix	The serum concentration of Methylprednisolone can be decreased when it is combined with Liotrix.	Approved
Liraglutide	The therapeutic efficacy of Liraglutide can be decreased when used in combination with Methylprednisolone.	Approved
Lisinopril	The serum concentration of Methylprednisolone can be increased when it is combined with Lisinopril.	Approved, Investigational
Lisofylline	The risk or severity of adverse effects can be increased when Lisofylline is combined with Methylprednisolone.	Investigational
Lisuride	The risk or severity of adverse effects can be increased when Lisuride is combined with Methylprednisolone.	Approved
Lomitapide	The serum concentration of Methylprednisolone can be increased when it is combined with Lomitapide.	Approved
Lonazolac	The risk or severity of adverse effects can be increased when Lonazolac is combined with Methylprednisolone.	Experimental
Loperamide	The serum concentration of Methylprednisolone can be increased when it is combined with Loperamide.	Approved
Lopinavir	The serum concentration of Methylprednisolone can be increased when it is combined with Lopinavir.	Approved
Loratadine	The serum concentration of Methylprednisolone can be increased when it is combined with Loratadine.	Approved
Lornoxicam	The risk or severity of adverse effects can be increased when Lornoxicam is combined with Methylprednisolone.	Approved
Losartan	The serum concentration of Methylprednisolone can be increased when it is combined with Losartan.	Approved
Lovastatin	The metabolism of Methylprednisolone can be decreased when combined with Lovastatin.	Approved, Investigational
Loxoprofen	The risk or severity of adverse effects can be increased when Loxoprofen is combined with Methylprednisolone.	Approved
Luliconazole	The serum concentration of Methylprednisolone can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The serum concentration of Methylprednisolone can be decreased when it is combined with Lumacaftor.	Approved
Lumiracoxib	The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Methylprednisolone.	Approved, Investigational
Lysergic Acid Diethylamide	The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Methylprednisolone.	Illicit, Withdrawn
Magaldrate	The bioavailability of Methylprednisolone can be decreased when combined with Magaldrate.	Withdrawn
Magnesium Hydroxide	The bioavailability of Methylprednisolone can be decreased when combined with Magnesium Hydroxide.	Approved
Magnesium oxide	The bioavailability of Methylprednisolone can be decreased when combined with Magnesium oxide.	Approved
Magnesium peroxide	The bioavailability of Methylprednisolone can be decreased when combined with Magnesium peroxide.	Experimental
Magnesium salicylate	The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Methylprednisolone.	Approved
Magnesium silicate	The bioavailability of Methylprednisolone can be decreased when combined with Magnesium silicate.	Experimental
Magnesium Trisilicate	The bioavailability of Methylprednisolone can be decreased when combined with Magnesium Trisilicate.	Approved
Malathion	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Malathion.	Approved, Investigational
Maprotiline	The serum concentration of Methylprednisolone can be increased when it is combined with Maprotiline.	Approved
Masoprocol	The risk or severity of adverse effects can be increased when Masoprocol is combined with Methylprednisolone.	Approved
Mebendazole	The serum concentration of Methylprednisolone can be increased when it is combined with Mebendazole.	Approved, Vet Approved
Meclofenamic acid	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Methylprednisolone.	Approved, Vet Approved
Mefenamic acid	The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Methylprednisolone.	Approved
Mefloquine	The serum concentration of Methylprednisolone can be increased when it is combined with Mefloquine.	Approved
Megestrol acetate	The serum concentration of Methylprednisolone can be increased when it is combined with Megestrol acetate.	Approved, Vet Approved
Meloxicam	The risk or severity of adverse effects can be increased when Meloxicam is combined with Methylprednisolone.	Approved, Vet Approved
Memantine	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Memantine.	Approved, Investigational
Meprobamate	The serum concentration of Methylprednisolone can be increased when it is combined with Meprobamate.	Approved, Illicit
Mesalazine	The risk or severity of adverse effects can be increased when Mesalazine is combined with Methylprednisolone.	Approved
Mesterolone	Methylprednisolone may increase the fluid retaining activities of Mesterolone.	Experimental
Mestranol	The serum concentration of Methylprednisolone can be increased when it is combined with Mestranol.	Approved
Metamizole	The risk or severity of adverse effects can be increased when Metamizole is combined with Methylprednisolone.	Withdrawn
Metergoline	The risk or severity of adverse effects can be increased when Metergoline is combined with Methylprednisolone.	Experimental
Metformin	The therapeutic efficacy of Metformin can be decreased when used in combination with Methylprednisolone.	Approved
Methadone	The serum concentration of Methylprednisolone can be increased when it is combined with Methadone.	Approved
Methallenestril	The serum concentration of Methylprednisolone can be increased when it is combined with Methallenestril.	Experimental
Methanesulfonyl Fluoride	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Methanesulfonyl Fluoride.	Investigational
Methyclothiazide	Methylprednisolone may increase the hypokalemic activities of Methyclothiazide.	Approved
Methyl salicylate	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Methyl salicylate.	Approved, Vet Approved
Methylergometrine	The risk or severity of adverse effects can be increased when Methylergometrine is combined with Methylprednisolone.	Approved
Methyltestosterone	Methylprednisolone may increase the fluid retaining activities of Methyltestosterone.	Approved
Methysergide	The risk or severity of adverse effects can be increased when Methysergide is combined with Methylprednisolone.	Approved
Metildigoxin	Metildigoxin may decrease the cardiotoxic activities of Methylprednisolone.	Experimental
Metoclopramide	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Metoclopramide.	Approved, Investigational
Metolazone	Methylprednisolone may increase the hypokalemic activities of Metolazone.	Approved
Metoprolol	The serum concentration of Methylprednisolone can be increased when it is combined with Metoprolol.	Approved, Investigational
Mevastatin	The serum concentration of Mevastatin can be increased when it is combined with Methylprednisolone.	Experimental
Mibefradil	The serum concentration of Methylprednisolone can be increased when it is combined with Mibefradil.	Withdrawn
Miconazole	The serum concentration of Methylprednisolone can be increased when it is combined with Miconazole.	Approved, Investigational, Vet Approved
Midazolam	The serum concentration of Methylprednisolone can be decreased when it is combined with Midazolam.	Approved, Illicit
Mifepristone	The serum concentration of Methylprednisolone can be increased when it is combined with Mifepristone.	Approved, Investigational
Miglitol	The therapeutic efficacy of Miglitol can be decreased when used in combination with Methylprednisolone.	Approved
Miglustat	The therapeutic efficacy of Miglustat can be decreased when used in combination with Methylprednisolone.	Approved
Minaprine	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Minaprine.	Approved
Mitiglinide	The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Methylprednisolone.	Approved, Investigational
Mitomycin	The serum concentration of Methylprednisolone can be increased when it is combined with Mitomycin.	Approved
Mitotane	The serum concentration of Methylprednisolone can be decreased when it is combined with Mitotane.	Approved
Mitoxantrone	The serum concentration of Methylprednisolone can be decreased when it is combined with Mitoxantrone.	Approved, Investigational
Mivacurium	Mivacurium may increase the adverse neuromuscular activities of Methylprednisolone.	Approved
Mizoribine	The risk or severity of adverse effects can be increased when Mizoribine is combined with Methylprednisolone.	Investigational
Mofebutazone	The risk or severity of adverse effects can be increased when Mofebutazone is combined with Methylprednisolone.	Experimental
Morphine	The serum concentration of Methylprednisolone can be increased when it is combined with Morphine.	Approved, Investigational
Moxestrol	The serum concentration of Methylprednisolone can be increased when it is combined with Moxestrol.	Experimental
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Methylprednisolone.	Approved, Investigational
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Methylprednisolone.	Approved
Nabumetone	The risk or severity of adverse effects can be increased when Nabumetone is combined with Methylprednisolone.	Approved
Nafamostat	The risk or severity of adverse effects can be increased when Nafamostat is combined with Methylprednisolone.	Approved, Investigational
Naftifine	The risk or severity of adverse effects can be increased when Naftifine is combined with Methylprednisolone.	Approved
Nalidixic Acid	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Nalidixic Acid.	Approved
Naltrexone	The serum concentration of Methylprednisolone can be increased when it is combined with Naltrexone.	Approved, Investigational, Vet Approved
Nandrolone	Methylprednisolone may increase the fluid retaining activities of Nandrolone.	Experimental
Naproxen	The risk or severity of adverse effects can be increased when Naproxen is combined with Methylprednisolone.	Approved, Vet Approved
Naringenin	The serum concentration of Methylprednisolone can be increased when it is combined with Naringenin.	Experimental
Natalizumab	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Natalizumab.	Approved, Investigational
Nateglinide	The therapeutic efficacy of Nateglinide can be decreased when used in combination with Methylprednisolone.	Approved, Investigational
Nefazodone	The serum concentration of Methylprednisolone can be increased when it is combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The serum concentration of Methylprednisolone can be increased when it is combined with Nelfinavir.	Approved
Nemonoxacin	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Nemonoxacin.	Investigational
Neostigmine	The serum concentration of Methylprednisolone can be increased when it is combined with Neostigmine.	Approved, Vet Approved
Nepafenac	The risk or severity of adverse effects can be increased when Nepafenac is combined with Methylprednisolone.	Approved
Netupitant	The serum concentration of Methylprednisolone can be increased when it is combined with Netupitant.	Approved
Nevirapine	The serum concentration of Methylprednisolone can be decreased when it is combined with Nevirapine.	Approved
Nicardipine	The serum concentration of Methylprednisolone can be increased when it is combined with Nicardipine.	Approved
Nicergoline	The risk or severity of adverse effects can be increased when Nicergoline is combined with Methylprednisolone.	Approved
Nicorandil	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Nicorandil.	Approved
Nifedipine	The serum concentration of Methylprednisolone can be decreased when it is combined with Nifedipine.	Approved
Nifenazone	The risk or severity of adverse effects can be increased when Nifenazone is combined with Methylprednisolone.	Experimental
Niflumic Acid	The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Methylprednisolone.	Approved
Nilotinib	The metabolism of Methylprednisolone can be decreased when combined with Nilotinib.	Approved, Investigational
Nimesulide	The risk or severity of adverse effects can be increased when Nimesulide is combined with Methylprednisolone.	Approved, Withdrawn
Nisoldipine	The serum concentration of Methylprednisolone can be increased when it is combined with Nisoldipine.	Approved
Nitrazepam	The serum concentration of Methylprednisolone can be increased when it is combined with Nitrazepam.	Approved
Nitrendipine	The serum concentration of Methylprednisolone can be increased when it is combined with Nitrendipine.	Approved
Nitroaspirin	The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Methylprednisolone.	Investigational
Norethisterone	The serum concentration of Methylprednisolone can be decreased when it is combined with Norethisterone.	Approved
Norfloxacin	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Norfloxacin.	Approved
Olaparib	The metabolism of Methylprednisolone can be decreased when combined with Olaparib.	Approved
Oleandrin	Oleandrin may decrease the cardiotoxic activities of Methylprednisolone.	Experimental
Olopatadine	The risk or severity of adverse effects can be increased when Olopatadine is combined with Methylprednisolone.	Approved
Olsalazine	The risk or severity of adverse effects can be increased when Olsalazine is combined with Methylprednisolone.	Approved
Omeprazole	The serum concentration of Methylprednisolone can be increased when it is combined with Omeprazole.	Approved, Investigational, Vet Approved
Orgotein	The risk or severity of adverse effects can be increased when Orgotein is combined with Methylprednisolone.	Vet Approved
Osimertinib	The serum concentration of Methylprednisolone can be increased when it is combined with Osimertinib.	Approved
Ouabain	Ouabain may decrease the cardiotoxic activities of Methylprednisolone.	Approved
Oxandrolone	Methylprednisolone may increase the fluid retaining activities of Oxandrolone.	Approved, Investigational
Oxaprozin	The risk or severity of adverse effects can be increased when Oxaprozin is combined with Methylprednisolone.	Approved
Oxolinic acid	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Oxolinic acid.	Experimental
Oxymetholone	Methylprednisolone may increase the fluid retaining activities of Oxymetholone.	Approved, Illicit
Oxyphenbutazone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Methylprednisolone.	Withdrawn
P-Nitrophenol	The serum concentration of Methylprednisolone can be increased when it is combined with P-Nitrophenol.	Experimental
Paclitaxel	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Methylprednisolone.	Approved, Vet Approved
Palbociclib	The serum concentration of Methylprednisolone can be increased when it is combined with Palbociclib.	Approved
Palmitic Acid	The serum concentration of Methylprednisolone can be increased when it is combined with Palmitic Acid.	Experimental
Pantoprazole	The serum concentration of Methylprednisolone can be increased when it is combined with Pantoprazole.	Approved
Paraoxon	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Paraoxon.	Experimental
Parecoxib	The risk or severity of adverse effects can be increased when Parecoxib is combined with Methylprednisolone.	Approved
Paroxetine	The serum concentration of Methylprednisolone can be increased when it is combined with Paroxetine.	Approved, Investigational
Parthenolide	The risk or severity of adverse effects can be increased when Parthenolide is combined with Methylprednisolone.	Investigational
Pazufloxacin	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Pazufloxacin.	Investigational
Pefloxacin	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Pefloxacin.	Approved
Pentobarbital	The serum concentration of Methylprednisolone can be decreased when it is combined with Pentobarbital.	Approved, Vet Approved
Pergolide	The risk or severity of adverse effects can be increased when Pergolide is combined with Methylprednisolone.	Approved, Vet Approved, Withdrawn
Perindopril	The serum concentration of Methylprednisolone can be increased when it is combined with Perindopril.	Approved
Peruvoside	Peruvoside may decrease the cardiotoxic activities of Methylprednisolone.	Experimental
Phenformin	The therapeutic efficacy of Phenformin can be decreased when used in combination with Methylprednisolone.	Approved, Withdrawn
Phenobarbital	The serum concentration of Methylprednisolone can be decreased when it is combined with Phenobarbital.	Approved
Phenylacetic acid	The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Methylprednisolone.	Approved
Phenylbutazone	The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Methylprednisolone.	Approved, Vet Approved
Phenylbutyric acid	The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Methylprednisolone.	Approved, Investigational
Phenytoin	The serum concentration of Methylprednisolone can be decreased when it is combined with Phenytoin.	Approved, Vet Approved
Physostigmine	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Physostigmine.	Approved
Pibrentasvir	The serum concentration of Methylprednisolone can be increased when it is combined with Pibrentasvir.	Approved
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Methylprednisolone.	Approved, Investigational
Pimozide	The serum concentration of Methylprednisolone can be increased when it is combined with Pimozide.	Approved
Pioglitazone	The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Methylprednisolone.	Approved, Investigational
Pipemidic acid	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Pipemidic acid.	Experimental
Piretanide	Methylprednisolone may increase the hypokalemic activities of Piretanide.	Experimental
Pirfenidone	The risk or severity of adverse effects can be increased when Pirfenidone is combined with Methylprednisolone.	Investigational
Piromidic acid	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Piromidic acid.	Experimental
Piroxicam	The risk or severity of adverse effects can be increased when Piroxicam is combined with Methylprednisolone.	Approved, Investigational
Pirprofen	The risk or severity of adverse effects can be increased when Pirprofen is combined with Methylprednisolone.	Experimental
Pitavastatin	The serum concentration of Pitavastatin can be increased when it is combined with Methylprednisolone.	Approved
Platelet Activating Factor	The serum concentration of Methylprednisolone can be decreased when it is combined with Platelet Activating Factor.	Experimental
Polyestradiol phosphate	The serum concentration of Methylprednisolone can be increased when it is combined with Polyestradiol phosphate.	Approved
Polythiazide	Methylprednisolone may increase the hypokalemic activities of Polythiazide.	Approved
Ponatinib	The serum concentration of Methylprednisolone can be increased when it is combined with Ponatinib.	Approved
Posaconazole	The serum concentration of Methylprednisolone can be increased when it is combined with Posaconazole.	Approved, Investigational, Vet Approved
Pramlintide	The therapeutic efficacy of Pramlintide can be decreased when used in combination with Methylprednisolone.	Approved, Investigational
Pranoprofen	The risk or severity of adverse effects can be increased when Pranoprofen is combined with Methylprednisolone.	Experimental
Pravastatin	The serum concentration of Methylprednisolone can be increased when it is combined with Pravastatin.	Approved
Prazosin	The serum concentration of Methylprednisolone can be increased when it is combined with Prazosin.	Approved
Prednisone	The serum concentration of Methylprednisolone can be increased when it is combined with Prednisone.	Approved, Vet Approved
Primidone	The serum concentration of Methylprednisolone can be decreased when it is combined with Primidone.	Approved, Vet Approved
Probenecid	The serum concentration of Methylprednisolone can be increased when it is combined with Probenecid.	Approved
Progesterone	The serum concentration of Methylprednisolone can be decreased when it is combined with Progesterone.	Approved, Vet Approved
Proglumetacin	The risk or severity of adverse effects can be increased when Proglumetacin is combined with Methylprednisolone.	Experimental
Promestriene	The serum concentration of Methylprednisolone can be increased when it is combined with Promestriene.	Investigational
Promethazine	The serum concentration of Methylprednisolone can be increased when it is combined with Promethazine.	Approved
Propacetamol	The risk or severity of adverse effects can be increased when Propacetamol is combined with Methylprednisolone.	Approved
Propafenone	The serum concentration of Methylprednisolone can be increased when it is combined with Propafenone.	Approved
Propranolol	The serum concentration of Methylprednisolone can be increased when it is combined with Propranolol.	Approved, Investigational
Propyphenazone	The risk or severity of adverse effects can be increased when Propyphenazone is combined with Methylprednisolone.	Experimental
Proquazone	The risk or severity of adverse effects can be increased when Proquazone is combined with Methylprednisolone.	Experimental
Proscillaridin	Proscillaridin may decrease the cardiotoxic activities of Methylprednisolone.	Experimental
Protriptyline	The serum concentration of Methylprednisolone can be increased when it is combined with Protriptyline.	Approved
Prulifloxacin	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Prulifloxacin.	Investigational
PTC299	The risk or severity of adverse effects can be increased when PTC299 is combined with Methylprednisolone.	Investigational
Pyridostigmine	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Pyridostigmine.	Approved
Quercetin	The serum concentration of Methylprednisolone can be increased when it is combined with Quercetin.	Experimental
Quinacrine	The serum concentration of Methylprednisolone can be increased when it is combined with Quinacrine.	Approved
Quinestrol	The serum concentration of Methylprednisolone can be increased when it is combined with Quinestrol.	Approved
Quinethazone	Methylprednisolone may increase the hypokalemic activities of Quinethazone.	Approved
Quinidine	The serum concentration of Methylprednisolone can be increased when it is combined with Quinidine.	Approved
Quinine	The serum concentration of Methylprednisolone can be increased when it is combined with Quinine.	Approved
Rabies virus inactivated antigen, A	The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Methylprednisolone.	Approved
Ranitidine	The serum concentration of Methylprednisolone can be increased when it is combined with Ranitidine.	Approved
Ranolazine	The serum concentration of Methylprednisolone can be increased when it is combined with Ranolazine.	Approved, Investigational
Rapacuronium	Rapacuronium may increase the adverse neuromuscular activities of Methylprednisolone.	Withdrawn
Reboxetine	The serum concentration of Methylprednisolone can be increased when it is combined with Reboxetine.	Approved, Investigational
Regorafenib	The serum concentration of Methylprednisolone can be increased when it is combined with Regorafenib.	Approved
Repaglinide	The therapeutic efficacy of Repaglinide can be decreased when used in combination with Methylprednisolone.	Approved, Investigational
Reserpine	The serum concentration of Methylprednisolone can be decreased when it is combined with Reserpine.	Approved
Resveratrol	The risk or severity of adverse effects can be increased when Resveratrol is combined with Methylprednisolone.	Experimental, Investigational
Rifabutin	The serum concentration of Methylprednisolone can be decreased when it is combined with Rifabutin.	Approved
Rifampicin	The serum concentration of Methylprednisolone can be decreased when it is combined with Rifampicin.	Approved
Rifapentine	The serum concentration of Methylprednisolone can be decreased when it is combined with Rifapentine.	Approved
Rilpivirine	The serum concentration of Methylprednisolone can be increased when it is combined with Rilpivirine.	Approved
Ritonavir	The serum concentration of Methylprednisolone can be increased when it is combined with Ritonavir.	Approved, Investigational
Rivastigmine	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Rivastigmine.	Approved, Investigational
Rofecoxib	The risk or severity of adverse effects can be increased when Rofecoxib is combined with Methylprednisolone.	Investigational, Withdrawn
Roflumilast	Roflumilast may increase the immunosuppressive activities of Methylprednisolone.	Approved
Rolapitant	The serum concentration of Methylprednisolone can be increased when it is combined with Rolapitant.	Approved
Rosiglitazone	The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Methylprednisolone.	Approved, Investigational
Rosoxacin	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Rosoxacin.	Approved
Rosuvastatin	The serum concentration of Rosuvastatin can be increased when it is combined with Methylprednisolone.	Approved
Rufloxacin	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Rufloxacin.	Experimental
Salicylamide	The risk or severity of adverse effects can be increased when Salicylamide is combined with Methylprednisolone.	Approved
Salicylic acid	The risk or severity of adverse effects can be increased when Salicylic acid is combined with Methylprednisolone.	Approved, Vet Approved
Salsalate	The risk or severity of adverse effects can be increased when Salsalate is combined with Methylprednisolone.	Approved
Saquinavir	The serum concentration of Methylprednisolone can be increased when it is combined with Saquinavir.	Approved, Investigational
Saxagliptin	The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Methylprednisolone.	Approved
Scopolamine	The serum concentration of Methylprednisolone can be increased when it is combined with Scopolamine.	Approved
Secoisolariciresinol	The serum concentration of Methylprednisolone can be increased when it is combined with Secoisolariciresinol.	Investigational
Selegiline	The serum concentration of Methylprednisolone can be increased when it is combined with Selegiline.	Approved, Investigational, Vet Approved
Semapimod	The risk or severity of adverse effects can be increased when Semapimod is combined with Methylprednisolone.	Investigational
Seratrodast	The risk or severity of adverse effects can be increased when Seratrodast is combined with Methylprednisolone.	Approved
Serrapeptase	The risk or severity of adverse effects can be increased when Serrapeptase is combined with Methylprednisolone.	Investigational
Sertraline	The serum concentration of Methylprednisolone can be increased when it is combined with Sertraline.	Approved
Sildenafil	The metabolism of Methylprednisolone can be decreased when combined with Sildenafil.	Approved, Investigational
Siltuximab	The serum concentration of Methylprednisolone can be decreased when it is combined with Siltuximab.	Approved
Simeprevir	The serum concentration of Methylprednisolone can be increased when it is combined with Simeprevir.	Approved
Simvastatin	The serum concentration of Methylprednisolone can be increased when it is combined with Simvastatin.	Approved
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Methylprednisolone.	Approved
Sirolimus	The serum concentration of Methylprednisolone can be decreased when it is combined with Sirolimus.	Approved, Investigational
Sitafloxacin	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Sitafloxacin.	Experimental
Sitagliptin	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Methylprednisolone.	Approved, Investigational
Sorafenib	The serum concentration of Methylprednisolone can be increased when it is combined with Sorafenib.	Approved, Investigational
Sotagliflozin	The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Methylprednisolone.	Investigational
Sparfloxacin	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Sparfloxacin.	Approved
Spironolactone	The serum concentration of Methylprednisolone can be increased when it is combined with Spironolactone.	Approved
SRT501	The risk or severity of adverse effects can be increased when SRT501 is combined with Methylprednisolone.	Investigational
St. John's Wort	The serum concentration of Methylprednisolone can be decreased when it is combined with St. John's Wort.	Nutraceutical
Stanozolol	Methylprednisolone may increase the fluid retaining activities of Stanozolol.	Approved, Vet Approved
Staurosporine	The serum concentration of Methylprednisolone can be increased when it is combined with Staurosporine.	Experimental
Stiripentol	The serum concentration of Methylprednisolone can be increased when it is combined with Stiripentol.	Approved
Streptozocin	The serum concentration of Methylprednisolone can be decreased when it is combined with Streptozocin.	Approved
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Methylprednisolone.	Approved
Sulfinpyrazone	The serum concentration of Methylprednisolone can be increased when it is combined with Sulfinpyrazone.	Approved
Sulfisoxazole	The metabolism of Methylprednisolone can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Sulindac	The risk or severity of adverse effects can be increased when Sulindac is combined with Methylprednisolone.	Approved
Sulodexide	The therapeutic efficacy of Sulodexide can be decreased when used in combination with Methylprednisolone.	Approved, Investigational
Sumatriptan	The serum concentration of Methylprednisolone can be increased when it is combined with Sumatriptan.	Approved, Investigational
Sunitinib	The serum concentration of Methylprednisolone can be increased when it is combined with Sunitinib.	Approved, Investigational
Suprofen	The risk or severity of adverse effects can be increased when Suprofen is combined with Methylprednisolone.	Approved, Withdrawn
Suxibuzone	The risk or severity of adverse effects can be increased when Suxibuzone is combined with Methylprednisolone.	Experimental
Synthetic Conjugated Estrogens, A	The serum concentration of Methylprednisolone can be increased when it is combined with Synthetic Conjugated Estrogens, A.	Approved
Synthetic Conjugated Estrogens, B	The serum concentration of Methylprednisolone can be increased when it is combined with Synthetic Conjugated Estrogens, B.	Approved
Tacrine	The serum concentration of Methylprednisolone can be increased when it is combined with Tacrine.	Withdrawn
Tacrolimus	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Methylprednisolone.	Approved, Investigational
Tamoxifen	The serum concentration of Methylprednisolone can be decreased when it is combined with Tamoxifen.	Approved
Tarenflurbil	The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Methylprednisolone.	Investigational
Taurocholic Acid	The serum concentration of Methylprednisolone can be increased when it is combined with Taurocholic Acid.	Experimental
Telaprevir	The serum concentration of Telaprevir can be decreased when it is combined with Methylprednisolone.	Withdrawn
Telithromycin	The serum concentration of Methylprednisolone can be increased when it is combined with Telithromycin.	Approved
Telmisartan	The serum concentration of Methylprednisolone can be increased when it is combined with Telmisartan.	Approved, Investigational
Temafloxacin	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Temafloxacin.	Withdrawn
Temsirolimus	The serum concentration of Methylprednisolone can be increased when it is combined with Temsirolimus.	Approved
Tenidap	The risk or severity of adverse effects can be increased when Tenidap is combined with Methylprednisolone.	Experimental
Tenoxicam	The risk or severity of adverse effects can be increased when Tenoxicam is combined with Methylprednisolone.	Approved
Tepoxalin	The risk or severity of adverse effects can be increased when Tepoxalin is combined with Methylprednisolone.	Vet Approved
Terazosin	The serum concentration of Methylprednisolone can be increased when it is combined with Terazosin.	Approved
Terfenadine	The serum concentration of Methylprednisolone can be increased when it is combined with Terfenadine.	Withdrawn
Terguride	The risk or severity of adverse effects can be increased when Terguride is combined with Methylprednisolone.	Experimental
Teriflunomide	The risk or severity of adverse effects can be increased when Teriflunomide is combined with Methylprednisolone.	Approved
Tesmilifene	The serum concentration of Methylprednisolone can be decreased when it is combined with Tesmilifene.	Investigational
Testosterone	The serum concentration of Methylprednisolone can be increased when it is combined with Testosterone.	Approved, Investigational
Tiaprofenic acid	The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Methylprednisolone.	Approved
Tibolone	The serum concentration of Methylprednisolone can be increased when it is combined with Tibolone.	Approved
Ticagrelor	The serum concentration of Methylprednisolone can be increased when it is combined with Ticagrelor.	Approved
Ticlopidine	The metabolism of Methylprednisolone can be decreased when combined with Ticlopidine.	Approved
Tinoridine	The risk or severity of adverse effects can be increased when Tinoridine is combined with Methylprednisolone.	Investigational
Tocilizumab	The serum concentration of Methylprednisolone can be decreased when it is combined with Tocilizumab.	Approved
Tofacitinib	Methylprednisolone may increase the immunosuppressive activities of Tofacitinib.	Approved, Investigational
Tolazamide	The therapeutic efficacy of Tolazamide can be decreased when used in combination with Methylprednisolone.	Approved
Tolbutamide	The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Methylprednisolone.	Approved
Tolfenamic Acid	The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Methylprednisolone.	Approved
Tolmetin	The risk or severity of adverse effects can be increased when Tolmetin is combined with Methylprednisolone.	Approved
Tolvaptan	The serum concentration of Methylprednisolone can be increased when it is combined with Tolvaptan.	Approved
Torasemide	Methylprednisolone may increase the hypokalemic activities of Torasemide.	Approved
Tranilast	The risk or severity of adverse effects can be increased when Tranilast is combined with Methylprednisolone.	Approved, Investigational
Trastuzumab	Trastuzumab may increase the cardiotoxic activities of Methylprednisolone.	Approved, Investigational
Trazodone	The serum concentration of Methylprednisolone can be decreased when it is combined with Trazodone.	Approved, Investigational
Tribenoside	The risk or severity of adverse effects can be increased when Tribenoside is combined with Methylprednisolone.	Experimental
Trichlorfon	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Trichlorfon.	Vet Approved
Trichlormethiazide	Methylprednisolone may increase the hypokalemic activities of Trichlormethiazide.	Approved, Vet Approved
Trifluoperazine	The serum concentration of Methylprednisolone can be increased when it is combined with Trifluoperazine.	Approved
Triflupromazine	The serum concentration of Methylprednisolone can be increased when it is combined with Triflupromazine.	Approved, Vet Approved
Trimethoprim	The serum concentration of Methylprednisolone can be decreased when it is combined with Trimethoprim.	Approved, Vet Approved
Trimipramine	The serum concentration of Methylprednisolone can be increased when it is combined with Trimipramine.	Approved
Triptolide	The risk or severity of adverse effects can be increased when Triptolide is combined with Methylprednisolone.	Investigational
Troglitazone	The therapeutic efficacy of Troglitazone can be decreased when used in combination with Methylprednisolone.	Withdrawn
Troleandomycin	The serum concentration of Methylprednisolone can be increased when it is combined with Troleandomycin.	Approved
Trovafloxacin	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Trovafloxacin.	Approved, Withdrawn
Tubocurarine	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Tubocurarine.	Approved
Ubidecarenone	The serum concentration of Ubidecarenone can be increased when it is combined with Methylprednisolone.	Experimental
Valdecoxib	The risk or severity of adverse effects can be increased when Valdecoxib is combined with Methylprednisolone.	Investigational, Withdrawn
Velpatasvir	The serum concentration of Methylprednisolone can be increased when it is combined with Velpatasvir.	Approved
Venlafaxine	The metabolism of Methylprednisolone can be decreased when combined with Venlafaxine.	Approved
Verapamil	The metabolism of Methylprednisolone can be decreased when combined with Verapamil.	Approved
Vildagliptin	The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Methylprednisolone.	Approved, Investigational
Vinblastine	The serum concentration of Methylprednisolone can be decreased when it is combined with Vinblastine.	Approved
Vincristine	The serum concentration of Methylprednisolone can be decreased when it is combined with Vincristine.	Approved, Investigational
Vinorelbine	The serum concentration of Methylprednisolone can be increased when it is combined with Vinorelbine.	Approved, Investigational
Voglibose	The therapeutic efficacy of Voglibose can be decreased when used in combination with Methylprednisolone.	Approved, Investigational
Voriconazole	The serum concentration of Methylprednisolone can be increased when it is combined with Voriconazole.	Approved, Investigational
Voxilaprevir	The serum concentration of Methylprednisolone can be increased when it is combined with Voxilaprevir.	Approved
Warfarin	Methylprednisolone may increase the anticoagulant activities of Warfarin.	Approved
Zaltoprofen	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Methylprednisolone.	Approved
Zeranol	The serum concentration of Methylprednisolone can be increased when it is combined with Zeranol.	Vet Approved
Zileuton	The risk or severity of adverse effects can be increased when Zileuton is combined with Methylprednisolone.	Approved, Investigational, Withdrawn
Zimelidine	The serum concentration of Methylprednisolone can be increased when it is combined with Zimelidine.	Withdrawn
Ziprasidone	The metabolism of Methylprednisolone can be decreased when combined with Ziprasidone.	Approved
Zomepirac	The risk or severity of adverse effects can be increased when Zomepirac is combined with Methylprednisolone.	Withdrawn

Food Interactions

Not Available

References

Synthesis Reference

Klaus Annen, Karl Petzoldt, Henry Laurent, Rudolf Wiechert, Helmut Hofmeister, "Novel 6.alpha.-methylprednisolone derivatives, their preparation, and their use." U.S. Patent US4587236, issued March, 1973.

US4587236

General References

Sloka JS, Stefanelli M: The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler. 2005 Aug;11(4):425-32. [PubMed:16042225]

External Links

Human Metabolome Database: HMDB15094
KEGG Drug: D00407
PubChem Compound: 6741
PubChem Substance: 46504885
ChemSpider: 6485
ChEBI: 6888
ChEMBL: CHEMBL650
Therapeutic Targets Database: DAP001040
PharmGKB: PA450466
RxList: RxList Drug Page
Drugs.com: Drugs.com Drug Page
Wikipedia: Methylprednisolone

ATC Codes

D07CA02 — Methylprednisolone and antibiotics

S01CA08 — Methylprednisolone and antiinfectives

D07AC14 — Methylprednisolone aceponate

D07AA01 — Methylprednisolone

D10AA02 — Methylprednisolone

H02AB04 — Methylprednisolone

H02BX01 — Methylprednisolone, combinations

AHFS Codes

68:04.00 — Adrenals
84:06.00 — Anti-inflammatory Agents
84:04.04 — Antibiotics
84:28.00 — Keratolytic Agents

FDA label

Download (244 KB)

MSDS

Download (72.6 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Active Not Recruiting	Treatment	CHRONIC POST-TRAUMATIC NEUROPATHIC PAIN IN ANKLE AND FOOT	1
0	Active Not Recruiting	Treatment	Friedreich's Ataxia	1
0	Completed	Basic Science	Innate Immunity	1
0	Enrolling by Invitation	Treatment	Raynaud Phenomena / Sclerosis, Progressive Systemic	1
0	Terminated	Treatment	Complication of Anesthesia During Pregnancy, Unspecified / Fevers / Labour Pain	1
1	Active Not Recruiting	Treatment	Progressive Multiple Sclerosis	1
1	Completed	Basic Science	Biological Availability	1
1	Completed	Basic Science	Normal Physiology	1
1	Completed	Supportive Care	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous/Nonmalignant Condition	1
1	Completed	Treatment	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous/Nonmalignant Condition / Small Intestine Cancer	1
1	Completed	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
1	Completed	Treatment	Disseminated Sclerosis	2
1	Completed	Treatment	Drug Interactions	1
1	Completed	Treatment	Neuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific	1
1	Completed	Treatment	Osteoarthritis of the Knees	1
1	Recruiting	Treatment	Congenital Hypoplastic Anemia	1
1	Recruiting	Treatment	Contiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia	1
1	Recruiting	Treatment	Graft Versus Host Disease (GVHD) / Sickle Cell Disorders	1
1	Recruiting	Treatment	Status Asthmaticus	1
1	Terminated	Not Available	Disseminated Sclerosis / Healthy Volunteers	1
1	Terminated	Treatment	Rheumatoid Arthritis	1
1	Unknown Status	Supportive Care	Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	1
1	Unknown Status	Treatment	Leukemias / Myelodysplastic Syndromes	1
1	Unknown Status	Treatment	Malignant Lymphomas	1
1	Unknown Status	Treatment	Neuromyelitis Optica	1
1	Unknown Status	Treatment	Ocular GVHD	1
1	Unknown Status	Treatment	Unspecified Childhood Solid Tumor, Protocol Specific	1
1	Withdrawn	Basic Science	Therapeutic Equivalency	3
1, 2	Active Not Recruiting	Treatment	Classical Hodgkin Lymphoma	1
1, 2	Completed	Prevention	Ovarian Hyperstimulation Syndrome	1
1, 2	Completed	Treatment	Acute Lymphocytic Leukemia (ALL) / Leukemias	1
1, 2	Completed	Treatment	Congenital Hypoplastic Anemia	1
1, 2	Completed	Treatment	Kidney Diseases / Transplantation, Kidney	1
1, 2	Completed	Treatment	Leukemias	1
1, 2	Completed	Treatment	Spinal Cord Injuries (SCI)	2
1, 2	Completed	Treatment	Systemic Lupus Erythematosus (SLE)	1
1, 2	Not Yet Recruiting	Prevention	Noise Induced Hearing Loss	1
1, 2	Recruiting	Prevention	Cognitive Retention Disorder / Postoperative Complications	1
1, 2	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Myeloid Leukemia (CML) / Juvenile Myelomonocytic Leukemia (JMML) / Lymphoma (Hodgkin's and Non-Hodgkin's) / Myelodysplastic Syndromes (MDS)	1
1, 2	Recruiting	Treatment	Congenital Hypoplastic Anemia	1
1, 2	Recruiting	Treatment	Drug-Induced Liver Injury, Chronic	1
1, 2	Recruiting	Treatment	Inhospital Cardiac Arrest	1
1, 2	Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML) / Leukemias / Myelodysplastic Syndrome	1
1, 2	Terminated	Treatment	Leukemias	1
1, 2	Terminated	Treatment	Leukemias / Myeloproliferative Disorders / Plasma Cell Myeloma	1
1, 2	Unknown Status	Not Available	Atherosclerosis	1
2	Active Not Recruiting	Treatment	Adult Acute Lymphoblastic Leukemia in Remission / Adult B Acute Lymphoblastic Leukemia / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Adult L1 Acute Lymphoblastic Leukemia / Adult L2 Acute Lymphoblastic Leukemia / Adult T Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia	1
2	Active Not Recruiting	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)	2
2	Active Not Recruiting	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
2	Active Not Recruiting	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	1
2	Active Not Recruiting	Treatment	Leukemias	1
2	Active Not Recruiting	Treatment	Lung Cancers / Melanoma / Renal Cell Adenocarcinoma	1
2	Active Not Recruiting	Treatment	Lymphoproliferative Disorders	1
2	Active Not Recruiting	Treatment	Malignant Lymphomas	1
2	Active Not Recruiting	Treatment	Multiple Myeloma (MM)	1
2	Active Not Recruiting	Treatment	Nephritis, Lupus	1
2	Active Not Recruiting	Treatment	Relapsing Remitting Multiple Sclerosis (RRMS)	1
2	Active Not Recruiting	Treatment	Transplantation, Kidney	1
2	Completed	Diagnostic	Malignant Lymphomas	1
2	Completed	Prevention	Hyperalgesia / Knee Joint Osteoarthrosis / Severe Movement Related Pain	1
2	Completed	Supportive Care	Cancer, Breast / Cancer, Ovarian / Chronic Myeloproliferative Disorders / Gestational Trophoblastic Disease / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Neuroblastomas / Testicular germ cell tumour	2
2	Completed	Supportive Care	Cancers	1
2	Completed	Supportive Care	Malignant Lymphomas / Neutropenias	1
2	Completed	Treatment	Abdominal wall neoplasm / Carcinomatosis / Intestinal Obstruction	1
2	Completed	Treatment	Accelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Acute Promyelocytic Leukemia (M3) / Adult Erythroleukemia (M6a) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Pure Erythroid Leukemia (M6b) / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Burkitt's Lymphoma / Childhood Acute Erythroleukemia (M6) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myeloid Leukemia in Remission / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Acute Promyelocytic Leukemia (M3) / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)	1
2	Completed	Treatment	Accelerated Phase Chronic Myelogenous Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Phase Chronic Myelogenous Leukemia / De Novo Myelodysplastic Syndromes / Disseminated Neuroblastoma / Juvenile Myelomonocytic Leukemia / Previously Treated Childhood Rhabdomyosarcoma / Previously Treated Myelodysplastic Syndromes / Pulmonary Complications / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Neuroblastoma / Recurrent Wilms Tumor and Other Childhood Kidney Tumors / Recurrent/Refractory Childhood Hodgkin Lymphoma / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes	1
2	Completed	Treatment	Acute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS) / Postoperative Complications	1
2	Completed	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Leukemias	1
2	Completed	Treatment	Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Erythroleukemia (M6a) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Pure Erythroid Leukemia (M6b) / B-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Burkitt's Lymphoma / Childhood Acute Erythroleukemia (M6) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Minimally Differentiated Myeloid Leukemia (M0) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Juvenile Myelomonocytic Leukemia / Leukemia, Prolymphocytic / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Secondary Myelofibrosis / Splenic Marginal Zone Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia / T-Cell Large Granular Lymphocyte Leukemia / Waldenstrom's Macroglobulinemia (WM)	1
2	Completed	Treatment	Adverse Effect of Radiation Therapy / Brain Necrosis / Nasopharyngeal Carcinoma	1
2	Completed	Treatment	Amyotrophic Lateral Sclerosis (ALS)	1
2	Completed	Treatment	Aplastic Anaemia (AA)	1
2	Completed	Treatment	Aplastic Anaemia (AA) / Myelodysplastic Syndrome	1
2	Completed	Treatment	Blood Cancers / CLL / Graft Versus Host Disease (GVHD) / Hodgkins Disease (HD) / Leukemias / Malignancies / NHL / Smith-Magenis Syndrome	1
2	Completed	Treatment	Bursitis	1
2	Completed	Treatment	Cancer, Breast / Cancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cancer	1
2	Completed	Treatment	Childhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Untreated Childhood Acute Lymphoblastic Leukemia	1
2	Completed	Treatment	Chronic B-Lymphocytic Leukemia	1
2	Completed	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Non-Hodgkin's Lymphoma (NHL)	1
2	Completed	Treatment	Congenital Amegakaryocytic Thrombocytopenia / Congenital Hypoplastic Anemia / Leukemias / Myelodysplastic Syndromes / Severe Congenital Neutropenia	1
2	Completed	Treatment	Connective Tissue Diseases / Dermatomyositis / Vasculitis / Vasculitis, Hypersensitivity	1
2	Completed	Treatment	Giant Cell Myocarditis / Myocarditis	1
2	Completed	Treatment	Graft Versus Host Disease (GVHD)	1
2	Completed	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
2	Completed	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Neuroblastomas	1
2	Completed	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes	1
2	Completed	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Thymic Carcinoma	1
2	Completed	Treatment	Granulomatosis With Polyangiitis / Microscopic Polyangiitis / Renal Limited Vasculitis	1
2	Completed	Treatment	Hantavirus Infections	1
2	Completed	Treatment	Hormone Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer	1
2	Completed	Treatment	Kidney Failure,Chronic / Transplantation, Kidney	1
2	Completed	Treatment	Leukemias	3
2	Completed	Treatment	Leukemias / Malignant Lymphomas	1
2	Completed	Treatment	Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic-Myeloproliferative Diseases	1
2	Completed	Treatment	Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
2	Completed	Treatment	Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms	1
2	Completed	Treatment	Leukemias / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	1
2	Completed	Treatment	Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
2	Completed	Treatment	Lupus Erythematosus, Systemic	1
2	Completed	Treatment	Malignant Lymphomas	3
2	Completed	Treatment	Nephritis, Lupus	1
2	Completed	Treatment	Pelvic Girdle Pain	1
2	Completed	Treatment	Progressive Multiple Sclerosis	1
2	Completed	Treatment	Rejection, Transplant	1
2	Completed	Treatment	Relapsing Remitting Multiple Sclerosis (RRMS)	1
2	Completed	Treatment	Rheumatoid Arthritis	2
2	Completed	Treatment	Suspected Appendicitis	1
2	Enrolling by Invitation	Treatment	Disseminated Sclerosis	1
2	Enrolling by Invitation	Treatment	Graft Versus Host Disease (GVHD)	1
2	Not Yet Recruiting	Treatment	Acute-graft-versus-host Disease	1
2	Not Yet Recruiting	Treatment	Immune Thrombocytopenia	1
2	Not Yet Recruiting	Treatment	Systemic Lupus Erythematosus Arthritis	1
2	Recruiting	Treatment	Acute Graft Versus Host Disease	1
2	Recruiting	Treatment	Anaplastic Large Cell Lymphoma, ALK-Negative / Angioimmunoblastic T-Cell Lymphoma / Hepatosplenic Gamma/ Delta T-cell Lymphoma / Peripheral T-cell Lymphoma NOS	1
2	Recruiting	Treatment	Aplastic Anaemia (AA) / Hypoplastic Myelodysplastic Syndrome	1
2	Recruiting	Treatment	Cerebral Radiation Necrosis	1
2	Recruiting	Treatment	Congenital Hypoplastic Anemia	1
2	Recruiting	Treatment	Graft Versus Host Disease (GVHD)	1
2	Recruiting	Treatment	Henoch-Schoenlein Purpura Nephritis	1
2	Recruiting	Treatment	IgA Glomerulonephritis / Necrosis / Peripapillary Crescent / Steroid Nephropathy	1
2	Recruiting	Treatment	Leukemias	5
2	Recruiting	Treatment	Multiple Myeloma (MM)	1
2	Recruiting	Treatment	Multiple Sclerosis, Chronic Progressive / Nervous System Diseases	1
2	Recruiting	Treatment	Nephritis, Lupus	1
2	Recruiting	Treatment	Non-Hodgkin's Lymphoma (NHL)	1
2	Recruiting	Treatment	Plasma Cell Myeloma	1
2	Recruiting	Treatment	Transplant, Kidney	1
2	Terminated	Not Available	Acute Exacerbation of Remitting Relapsing Multiple Sclerosis / Clinically Isolated Syndrome (CIS)	1
2	Terminated	Treatment	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	1
2	Terminated	Treatment	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	1
2	Terminated	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Unusual Cancers of Childhood	1
2	Terminated	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Myelodysplastic/Myeloproliferative Diseases	1
2	Terminated	Treatment	End-Stage Renal Disease (ESRD)	1
2	Terminated	Treatment	Graves Ophthalmopathy	1
2	Terminated	Treatment	Haematological Malignancies	1
2	Terminated	Treatment	Insufficiency; Hepatic, Postoperative / Ischemic Reperfusion Injury / Neoplasms, Hepatic	1
2	Terminated	Treatment	Leukemias	1
2	Terminated	Treatment	Leukemias / Myelodysplastic Syndromes	1
2	Terminated	Treatment	Non-Hodgkin's Lymphoma (NHL)	1
2	Terminated	Treatment	Primary Renal Allograft Candidate / Transplantation, Kidney	1
2	Terminated	Treatment	Primary Simultaneous Kidney and Pancreas Allograft Candidates / Simultaneous Kidney and Pancreas Transplantation	1
2	Terminated	Treatment	Rheumatoid Arthritis	3
2	Terminated	Treatment	Spondylarthropathy	1
2	Terminated	Treatment	Transplant, Kidney	1
2	Terminated	Treatment	Transplantation, Kidney	1
2	Terminated	Treatment	Transplantation, Kidney / Transplantation, Renal	1
2	Unknown Status	Treatment	Acute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS)	1
2	Unknown Status	Treatment	Ankylosing Spondylitis (AS)	1
2	Unknown Status	Treatment	Childhood Langerhans Cell Histiocytosis / Congenital Hypoplastic Anemia / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Neuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific	1
2	Unknown Status	Treatment	Early and Severe Systemic Sclerosis	1
2	Unknown Status	Treatment	Elective Cardiac Surgery	1
2	Unknown Status	Treatment	Leukemias	1
2	Unknown Status	Treatment	Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	1
2	Unknown Status	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL)	1
2	Unknown Status	Treatment	Malignant Lymphomas	1
2	Unknown Status	Treatment	Primary Central Nervous System Lymphoma (PCNSL)	1
2	Withdrawn	Treatment	Acute Graft Versus Host Disease / Intestinal Graft Versus Host Disease	1
2	Withdrawn	Treatment	Adult Non-Hodgkin's Lymphoma / Anaplastic Large Cell Lymphoma / Lymphoma, AIDS Related	1
2	Withdrawn	Treatment	Chronic Graft Versus Host Disease	1
2	Withdrawn	Treatment	Disseminated Sclerosis	1
2	Withdrawn	Treatment	Plasma Cell Myeloma	1
2	Withdrawn	Treatment	Systemic Lupus Erythematosus (SLE)	1
2, 3	Active Not Recruiting	Treatment	Aplastic Anaemia (AA) / Dyskeratosis Congenita	1
2, 3	Active Not Recruiting	Treatment	Childhood B Acute Lymphoblastic Leukemia / Childhood Burkitt Leukemia / Childhood Diffuse Large Cell Lymphoma / Mediastinal (Thymic) Large B-Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma	1
2, 3	Completed	Not Available	Degenerative Joint Disease	2
2, 3	Completed	Treatment	Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
2, 3	Completed	Treatment	Autoimmune Diseases / Scleroderma, Systemic / Sclerosis	1
2, 3	Completed	Treatment	Carpal Tunnel Syndrome (CTS)	1
2, 3	Completed	Treatment	Familial Lipoprotein Lipase Deficiency	1
2, 3	Completed	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes	1
2, 3	Completed	Treatment	Granulomatosis With Polyangiitis / Microscopic Polyangiitis / Vasculitis	1
2, 3	Completed	Treatment	Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes	1
2, 3	Completed	Treatment	Lumbosacral Radiculopathy	1
2, 3	Completed	Treatment	Menière's Disease	1
2, 3	Completed	Treatment	Ophthalmopathy, Thyroid-Associated	1
2, 3	Completed	Treatment	Optic Neuritis	1
2, 3	Completed	Treatment	Sinusitis	1
2, 3	Not Yet Recruiting	Treatment	Thyroid Eye Disease	1
2, 3	Recruiting	Prevention	Complications	1
2, 3	Recruiting	Treatment	Acute Alcoholic Hepatitis	1
2, 3	Recruiting	Treatment	Chronic Kidney Disease (CKD) / Gout Acute	1
2, 3	Recruiting	Treatment	Diabetes Complications / Neuropathic arthropathy	1
2, 3	Recruiting	Treatment	Leukemias	1
2, 3	Terminated	Treatment	Disseminated Sclerosis	1
2, 3	Terminated	Treatment	Lupus Erythematosus, Systemic	1
2, 3	Unknown Status	Treatment	Acute Lung Injury (ALI) / ARDS, Human	1
3	Active Not Recruiting	Prevention	Dysphasia	1
3	Active Not Recruiting	Treatment	Acute Undifferentiated Leukemia (AUL) / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
3	Active Not Recruiting	Treatment	Drug/Agent Toxicity by Tissue/Organ / Leukemias	1
3	Active Not Recruiting	Treatment	Transplantation, Kidney	1
3	Completed	Not Available	Degenerative Joint Disease	4
3	Completed	Prevention	Facial Paralysis	1
3	Completed	Prevention	Kidney Diseases	1
3	Completed	Prevention	Post-Extubation Laryngeal Edema	1
3	Completed	Prevention	Transplantation, Kidney	1
3	Completed	Supportive Care	Cancers / Pain	1
3	Completed	Supportive Care	Graft Versus Host Disease (GVHD)	1
3	Completed	Supportive Care	Graft Versus Host Disease (GVHD) / Recurrent Adult Acute Lymphoblastic Leukemia	1
3	Completed	Treatment	Abdominal Pain (AP)	1
3	Completed	Treatment	Cardiac Arrest	1
3	Completed	Treatment	Chronic Kidney Disease (CKD) / IgA Nephropathy	1
3	Completed	Treatment	Chronic Lung Disease of Prematurity	1
3	Completed	Treatment	Chronic Lung Diseases / Respiratory Distress Syndrome, Adult	1
3	Completed	Treatment	Community Acquired Respiratory Disease Syndrome	1
3	Completed	Treatment	Dexamethasone-induced Hiccup in Chemotherapy	1
3	Completed	Treatment	Graft Versus Host Disease (GVHD)	1
3	Completed	Treatment	Heart Diseases / Heart Transplantation	1
3	Completed	Treatment	Hemangiomas	1
3	Completed	Treatment	Idiopathic Pneumonia Syndrome / Pneumonia	1
3	Completed	Treatment	Immune Thrombocytopenic Purpura ( ITP )	1
3	Completed	Treatment	Leukemias	1
3	Completed	Treatment	Malignant Lymphomas	3
3	Completed	Treatment	Multiple Sclerosis, Chronic Progressive	1
3	Completed	Treatment	Nephritis, Lupus	1
3	Completed	Treatment	Radicular Low Back Pain	1
3	Completed	Treatment	Rheumatoid Arthritis	4
3	Completed	Treatment	Spinal Cord Injuries (SCI)	1
3	Completed	Treatment	Sudden Deafness	1
3	Completed	Treatment	Transplant; Failure, Kidney	1
3	Completed	Treatment	Transplantation, Kidney	2
3	Not Yet Recruiting	Treatment	Congenital Heart Disease in Children / Inflammatory Responses	1
3	Not Yet Recruiting	Treatment	Prostate Cancer	1
3	Recruiting	Treatment	Acute Graft-Versus-Host Disease	1
3	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / BCR-ABL1 Fusion Protein Expression / Minimal Residual Disease / Philadelphia Chromosome Positive / T Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
3	Recruiting	Treatment	Cardiopulmonary Bypass	1
3	Recruiting	Treatment	Chronic Subdural Hematomas	1
3	Recruiting	Treatment	Dry Eye Syndrome (DES) / Ophthalmopathy, Thyroid-Associated	1
3	Recruiting	Treatment	Glomerulonephritis membranous	1
3	Recruiting	Treatment	Glomerulonephritis, Membranous	1
3	Recruiting	Treatment	Glucocorticoid therapy / Immunocompromised Patients / Immunosuppressive Agents / Neoplasms / Neoplasms, Hematologic / Pneumocystis	1
3	Recruiting	Treatment	Lymphohistiocytosis, Hemophagocytic	2
3	Recruiting	Treatment	Thrombocytopenias	1
3	Suspended	Treatment	Spinal Cord Injuries (SCI)	1
3	Terminated	Treatment	Disseminated Sclerosis	1
3	Terminated	Treatment	Evidence of Liver Transplantation / Transplantations	1
3	Terminated	Treatment	Glomerulonephritis	1
3	Terminated	Treatment	Human Immunodeficiency Virus (HIV) Infections / Pneumonia, Pneumocystis Carinii	1
3	Terminated	Treatment	Malignant Lymphomas	1
3	Terminated	Treatment	Neuromyelitis Optica / Transverse Myelitis	1
3	Terminated	Treatment	Prostate Cancer	1
3	Terminated	Treatment	Systemic Lupus Erythematosus (SLE)	1
3	Unknown Status	Treatment	Chronic Lymphocytic Leukaemia (CLL)	1
3	Unknown Status	Treatment	Disseminated Sclerosis / Optic Neuritis	1
3	Unknown Status	Treatment	Leukemias / Malignant Lymphomas	1
3	Unknown Status	Treatment	Malignant Lymphomas	1
3	Unknown Status	Treatment	Multiple Myeloma and Plasma Cell Neoplasm	1
3	Unknown Status	Treatment	NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)	1
3	Unknown Status	Treatment	Relapsing Remitting Multiple Sclerosis (RRMS)	1
3	Unknown Status	Treatment	Urinary Tract Infections (UTIs)	1
3	Unknown Status	Treatment	Vestibular Neuritis	1
3	Unknown Status	Treatment	Synovitis of osteoarthritis	1
3	Withdrawn	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas	1
3	Withdrawn	Treatment	Human Immunodeficiency Virus (HIV) Infections / Pneumonia, Pneumocystis Carinii	1
4	Active Not Recruiting	Prevention	Infections, Cytomegalovirus / Transplantation Infection	1
4	Active Not Recruiting	Treatment	Plantar fascial fibromatosis	1
4	Completed	Not Available	Healthy Volunteers	1
4	Completed	Not Available	Relapsing Remitting Multiple Sclerosis (RRMS)	1
4	Completed	Prevention	Adrenocortical Deficiency / Hemodynamics Instability	1
4	Completed	Prevention	Delirium - Postoperative / Stress, Physiological	1
4	Completed	Prevention	Esophageal Diseases	1
4	Completed	Prevention	Hysterectomy / Methylprednisolone / Postoperative pain	1
4	Completed	Prevention	Transplantation, Kidney	2
4	Completed	Prevention	Transplantation, Liver	1
4	Completed	Supportive Care	Inflammatory Responses / LOS / Postoperative pain / Prophylaxis against postoperative nausea and vomiting / Sleeping Quality / Tiredness	1
4	Completed	Supportive Care	Inflammatory Responses / Postoperative pain / Prophylaxis against postoperative nausea and vomiting / Sleeping Quality / Tiredness	1
4	Completed	Treatment	Acute Asthma / Asthma Bronchial / Reactive Airway Exacerbation	1
4	Completed	Treatment	Adrenal Insufficiency / Tendinopathy	1
4	Completed	Treatment	Alopecia Totalis (AT) / Alopecia Universalis (AU) / Ophiasic Alopecia	1
4	Completed	Treatment	Arthralgia / TMJ	1
4	Completed	Treatment	Asthma Bronchial	1
4	Completed	Treatment	Atopic Dermatitis (AD)	1
4	Completed	Treatment	Carpal Tunnel Syndrome (CTS)	1
4	Completed	Treatment	Children / Chronic Rhinosinusitis	1
4	Completed	Treatment	Community Acquired Pneumonia (CAP)	1
4	Completed	Treatment	Crohn's Disease (CD)	1
4	Completed	Treatment	Disseminated Sclerosis	1
4	Completed	Treatment	HLA Sensitization	1
4	Completed	Treatment	Heart Transplantation	1
4	Completed	Treatment	Liver Cirrhosis / Liver Transplant Disorder	1
4	Completed	Treatment	Migrainous Headache	1
4	Completed	Treatment	Nephritis, Lupus	1
4	Completed	Treatment	Osteoarthritis of the Knees	1
4	Completed	Treatment	Plantar fascial fibromatosis	1
4	Completed	Treatment	Rejection, Transplant / Renal Failure / Transplantation, Kidney	1
4	Completed	Treatment	Relapsing Remitting Multiple Sclerosis (RRMS)	3
4	Completed	Treatment	Rheumatoid Arthritis	5
4	Completed	Treatment	Sciatica	1
4	Completed	Treatment	Sepsis	1
4	Completed	Treatment	Transplantation, Kidney	1
4	Completed	Treatment	Transplantation, Liver	1
4	Completed	Treatment	Viral Bronchiolitis	1
4	Completed	Treatment	Synovitis of osteoarthritis	2
4	Not Yet Recruiting	Not Available	Ulcerative Colitis (UC)	1
4	Not Yet Recruiting	Prevention	Graves Ophthalmopathy	1
4	Not Yet Recruiting	Treatment	Acromioclavicular Joint Resection / Acromioplasty / Arthroscopic Shoulder Surgery / Intra-articular Debridement / Subacromial Decompression	1
4	Not Yet Recruiting	Treatment	Osteoarthritis of the Knees	1
4	Not Yet Recruiting	Treatment	Post-operative Edema / Steroid Use	1
4	Recruiting	Prevention	End-Stage Renal Disease (ESRD)	1
4	Recruiting	Prevention	Migraines	1
4	Recruiting	Treatment	Adhesive Capsulitis	1
4	Recruiting	Treatment	C.Surgical Procedure / Cardiac	1
4	Recruiting	Treatment	Calcifying Tendinitis of Shoulder	1
4	Recruiting	Treatment	Chronic Obstructive Pulmonary Disease (COPD)	1
4	Recruiting	Treatment	Community Acquired Pneumonia (CAP)	1
4	Recruiting	Treatment	Crohn's Disease (CD) / Inflammatory Bowel Diseases (IBD)	1
4	Recruiting	Treatment	Disseminated Sclerosis	1
4	Recruiting	Treatment	Drug Interaction Potentiation / Transplantation, Kidney	1
4	Recruiting	Treatment	Fulminant Hepatic Failure	1
4	Recruiting	Treatment	Immunosuppression	1
4	Recruiting	Treatment	Implant or Graft; Rejection	1
4	Recruiting	Treatment	Thyroid Associated Ophthalmopathy	1
4	Recruiting	Treatment	Ulcerative Colitis (UC)	1
4	Recruiting	Treatment	Wegener's Granulomatosis or Microscopic Polyangiitis / Wegener's Granulomatosis, Microscopic Polyangiitis	1
4	Terminated	Treatment	Chronic Obstructive Pulmonary Disease (COPD)	1
4	Terminated	Treatment	Immune Reconstitution Inflammatory Syndrome / Progressive Multifocal Leukoencephalopathy	1
4	Terminated	Treatment	Transplants and Implants	1
4	Unknown Status	Treatment	Behcet's Syndrome	1
4	Unknown Status	Treatment	Cardiac Surgical Procedures / Cardiopulmonary Bypass / Systemic Inflammatory Response Syndrome (SIRS)	1
4	Unknown Status	Treatment	Endocrine ophthalmopathy	1
4	Unknown Status	Treatment	Mastectomy / Neoplasms, Breast	1
4	Unknown Status	Treatment	Transplantation, Renal	1
4	Withdrawn	Not Available	Asthma Bronchial	1
4	Withdrawn	Treatment	Demyelinating Disorders / Disseminated Sclerosis / Myelitis NOS / Neuritis / Optic Neuritis	1
4	Withdrawn	Treatment	Pediatric Crohn's Disease	1
Not Available	Active Not Recruiting	Treatment	Leukemias	1
Not Available	Completed	Not Available	Dermatitis, Contact	1
Not Available	Completed	Supportive Care	Inflammatory Reaction / Postoperative pain	1
Not Available	Completed	Supportive Care	Post-traumatic; Arthrosis / Synovitis of osteoarthritis	1
Not Available	Completed	Supportive Care	Synovitis of osteoarthritis	1
Not Available	Completed	Treatment	Abdominal Aortic Aneurysms (AAA)	1
Not Available	Completed	Treatment	Aortic Valve Stenosis	1
Not Available	Completed	Treatment	Biliary Atresia	1
Not Available	Completed	Treatment	Chronic Low Back Pain (CLBP)	1
Not Available	Completed	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
Not Available	Completed	Treatment	Congenital Heart Disease (CHD) / Disorder of Fetus or Newborn	1
Not Available	Completed	Treatment	Disc Disease	1
Not Available	Completed	Treatment	Edema / Pain / Trismus	1
Not Available	Completed	Treatment	End-Stage Renal Disease (ESRD)	1
Not Available	Completed	Treatment	Hand, Foot, and Mouth Disease	1
Not Available	Completed	Treatment	Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Nonmalignant Neoplasm / Unspecified Adult Solid Tumor, Protocol Specific	1
Not Available	Completed	Treatment	Pain, Chronic	1
Not Available	Completed	Treatment	Polyp of Nasal Sinus	1
Not Available	Completed	Treatment	Shoulder Pain / Subacromial Bursitis	1
Not Available	Completed	Treatment	Transplantation, Kidney	1
Not Available	Enrolling by Invitation	Prevention	Cervical Degenerative Disc Disease / Cervical Disc Herniation / Cervical Spondylotic Myelopathy / Osteoarthritis of Cervical Spine / Swallowing Disorders	1
Not Available	Not Yet Recruiting	Prevention	Aortic Dissection	1
Not Available	Not Yet Recruiting	Treatment	Alcoholic Hepatitis (AH)	1
Not Available	Not Yet Recruiting	Treatment	Osteoarthritis of the Glenohumeral Joint	1
Not Available	Recruiting	Not Available	Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / GYNAECOLOGICAL INFECTION / Headaches / Herpes Simplex Virus / Hospital-acquired bacterial pneumonia / Hypercholesterolaemia / Hyperlipidemias / Hypertensive / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal	1
Not Available	Recruiting	Not Available	Asthma Bronchial	1
Not Available	Recruiting	Not Available	Chronic Renal Failure (CRF)	1
Not Available	Recruiting	Not Available	Graves Ophthalmopathy	1
Not Available	Recruiting	Treatment	Biceps Tendonitis / Injections	1
Not Available	Recruiting	Treatment	Chronic Renal Failure (CRF)	1
Not Available	Recruiting	Treatment	Congenital Heart Disease (CHD) / Disorder of Fetus or Newborn	1
Not Available	Recruiting	Treatment	Disorder Related to Renal Transplantation / Effects of Immunosuppressant Therapy	1
Not Available	Recruiting	Treatment	IgA Glomerulonephritis	1
Not Available	Recruiting	Treatment	Immunosuppression	1
Not Available	Recruiting	Treatment	Knee Arthropathy	1
Not Available	Recruiting	Treatment	Mycoplasma Pneumoniae Pneumonia	1
Not Available	Recruiting	Treatment	Neuroma, Human Forefoot	1
Not Available	Recruiting	Treatment	Pneumonia, Pneumocystis	1
Not Available	Recruiting	Treatment	Traumatic Optic Neuropathy	1
Not Available	Recruiting	Treatment	Ventral Hernias	1
Not Available	Terminated	Other	Lumbar Back Pain / Lumbar Radiculitis / Lumbar Spine Disc Herniation	1
Not Available	Terminated	Treatment	Acute Graft Versus Host Disease	1
Not Available	Terminated	Treatment	Acute Respiratory Distress Syndrome (ARDS)	1
Not Available	Terminated	Treatment	Bruton's agammaglobulinemia / Chediak-Higashi Syndrome / Chronic Granulomatous Disease (CGD) / Common Variable Immunodeficiency / Familial Erythrophagocytic Lymphohistiocytosis / Graft Versus Host Disease (GVHD) / Immunologic Deficiency Syndromes / Leukocyte Adhesion Deficiency Syndrome / Lymphohistiocytosis, Hemophagocytic / Severe Combined Immunodeficiency / Virus-Associated Hemophagocytic Syndrome / Wiskott-Aldrich Syndrome (WAS) / X-Linked Hyper IgM Syndrome / X-Linked Lymphoproliferative Syndrome	1
Not Available	Terminated	Treatment	Chronic Myeloproliferative Disorders / Congenital Hypoplastic Anemia / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
Not Available	Terminated	Treatment	Disseminated Sclerosis	1
Not Available	Terminated	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	1
Not Available	Terminated	Treatment	Inflammatory Bowel Diseases (IBD)	1
Not Available	Terminated	Treatment	Refractory Mycoplasma Pneumoniae Pneumonia	1
Not Available	Terminated	Treatment	Shoulder Impingement Syndrome	1
Not Available	Unknown Status	Prevention	Heart Valve Diseases / Systemic Inflammatory Response Syndrome (SIRS)	1
Not Available	Unknown Status	Prevention	Leukemias	1
Not Available	Unknown Status	Treatment	Anemia, Hemolytic, Autoimmune / Arthritis, Juvenile Rheumatoid / Autoimmune Thrombocytopenic Purpura / Churg-Strauss Syndrome (CSS) / Giant Cells Arteritis / Graft Versus Host Disease (GVHD) / Granulomatosis With Polyangiitis / Polyarteritis Nodosa / Pure Red Cell Aplasia / Purpura, Schoenlein-Henoch / Rheumatoid Arthritis / Systemic Lupus Erythematosus (SLE) / Takayasu's Disease / Vasculitis, Hypersensitivity	1
Not Available	Unknown Status	Treatment	Aplastic Anaemia (AA) / Graft Versus Host Disease (GVHD)	1
Not Available	Unknown Status	Treatment	Carpal Tunnel Syndrome (CTS)	1
Not Available	Unknown Status	Treatment	Chronic Obstructive Pulmonary Disease (COPD)	2
Not Available	Unknown Status	Treatment	Disseminated Sclerosis / Optic Neuritis	1
Not Available	Unknown Status	Treatment	Osteoarthritis of the Knees	1
Not Available	Unknown Status	Treatment	Severe Acute Exacerbation of Chronic Hepatitis B	1
Not Available	Withdrawn	Diagnostic	Lung Cancers	1
Not Available	Withdrawn	Treatment	Bronchiolitis	1
Not Available	Withdrawn	Treatment	Dexamethasone / Hiccups	1

Pharmacoeconomics

Manufacturers

Pharmacia and upjohn co
Cadista pharmaceuticals inc
Duramed pharmaceuticals inc sub barr laboratories inc
Heather drug co inc
Par pharmaceutical inc
Sandoz inc
Vintage pharmaceuticals inc
Watson laboratories inc
Abbott laboratories hosp products div
Hemopharm usa corp
Hospira inc
Elkins sinn div ah robins co inc
Organon usa inc
Abraxis pharmaceutical products
App pharmaceuticals llc
Bedford laboratories
International medication systems ltd
Teva parenteral medicines inc

Packagers

Dosage forms

Form	Route	Strength
Injection, powder, lyophilized, for solution	Intramuscular; Intravenous	125 mg/2mL
Injection, powder, lyophilized, for solution	Intramuscular; Intravenous	40 mg/mL
Injection, suspension	Intralesional; Intramuscular; Intrasynovial; Soft tissue	20 mg/mL
Injection, suspension	Intralesional; Intramuscular; Intrasynovial; Soft tissue	40 mg/mL
Injection, suspension	Intralesional; Intramuscular; Intrasynovial; Soft tissue	80 mg/mL
Injection, suspension	Intramuscular	40 mg/1
Suspension	Intra-articular; Intralesional; Intramuscular; Intrasynovial	20 mg
Suspension	Intra-articular; Intralesional; Intramuscular; Intrasynovial	80 mg
Suspension	Intra-articular; Intralesional; Intramuscular; Intrasynovial	40 mg
Solution	Intra-articular; Intrabursal
Gel	Topical	10 mg/g
Tablet	Oral	2 mg/1
Tablet	Oral	32 mg/1
Tablet	Oral	16 mg
Tablet	Oral	4 mg
Cream	Topical	2.5 mg
Tablet	Oral	16 mg/1
Tablet	Oral	4 mg/1
Tablet	Oral	8 mg/1
Injection, suspension	Intra-articular; Intralesional; Intramuscular; Parenteral; Soft tissue	40 mg/mL
Injection, suspension	Intra-articular; Intralesional; Intramuscular; Parenteral; Soft tissue	80 mg/mL
Injection, suspension	Intra-articular; Intralesional; Intramuscular; Soft tissue	40 mg/mL
Injection, suspension	Intra-articular; Intralesional; Intramuscular; Soft tissue	80 mg/mL
Injection, suspension	Intramuscular; Intrasynovial; Soft tissue	40 mg/mL
Suspension	Intra-articular; Intramuscular; Intrasynovial; Soft tissue	40 mg
Suspension	Intra-articular; Intramuscular; Intrasynovial; Soft tissue	80 mg
Injection, powder, lyophilized, for solution	Intramuscular; Intravenous	1 g/16mL
Injection, powder, lyophilized, for solution	Intramuscular; Intravenous	125 mg/1
Injection, powder, lyophilized, for solution	Intramuscular; Intravenous	2 g/1
Injection, powder, lyophilized, for solution	Intramuscular; Intravenous	40 mg/1
Injection, powder, lyophilized, for solution	Intramuscular; Intravenous	500 mg/1
Powder, for solution	Intramuscular; Intravenous	1 g
Powder, for solution	Intramuscular; Intravenous	125 mg
Powder, for solution	Intramuscular; Intravenous	40 mg
Powder, for solution	Intramuscular; Intravenous	5 g
Powder, for solution	Intramuscular; Intravenous	500 mg
Powder, for solution	Intramuscular; Intravenous
Cream	Topical
Lotion	Topical
Kit
Kit	Epidural; Infiltration; Intramuscular; Intrasynovial; Soft tissue; Topical
Kit	Epidural; Infiltration; Intra-articular; Intralesional; Intramuscular; Soft tissue
Injection, powder, for solution	Intramuscular; Intravenous	1 g/mL
Injection, powder, for solution	Intramuscular; Intravenous	125 mg/mL
Injection, powder, for solution	Intramuscular; Intravenous	40 mg/mL
Injection, powder, for solution	Intramuscular; Intravenous	500 mg/mL
Injection, powder, for solution	Intravenous	1 g/1
Injection, powder, for solution	Intravenous	40 mg/1
Kit
Kit; powder	Intramuscular; Intravenous	1 g
Kit; powder	Intramuscular; Intravenous	125 mg
Kit; powder	Intramuscular; Intravenous	40 mg
Kit; powder	Intramuscular; Intravenous	500 mg
Kit; powder, for solution	Intramuscular; Intravenous	1 g
Kit; powder, for solution	Intramuscular; Intravenous	125 mg
Kit; powder, for solution	Intramuscular; Intravenous	40 mg
Kit; powder, for solution	Intramuscular; Intravenous	500 mg
Powder, for solution	Intravenous	125 mg/mL
Powder, for solution	Intramuscular; Intravenous; Rectal	125 mg
Powder, for solution	Intramuscular; Intravenous; Rectal	40 mg

Prices

Unit description	Cost	Unit
Methylprednisolone powder	96.25USD	g
Methylprednisolone ac powdr	40.09USD	g
Methylprednisolone ss 1 gm vial	31.2USD	vial
Solu-medrol 1 gm vial	24.43USD	vial
Solu-medrol (pf) 500 mg vial	20.9USD	vial
MethylPREDNISolone (Pak) 21 4 mg tablet Disp Pack	16.99USD	disp
Methylprednisolone 500 mg vial	15.6USD	vial
Solu-medrol 500 mg vial	12.9USD	vial
Depo-medrol 80 mg/ml vial	11.67USD	ml
Methylprednisolone 125 mg vial	10.0USD	vial
Methylprednisolone 80 mg/ml vial	9.12USD	ml
Depo-medrol 40 mg/ml vial	6.41USD	ml
Solu-medrol (pf) 125 mg vial	5.83USD	vial
Methylprednisolone 40 mg/ml vial	5.22USD	ml
Medrol 32 mg tablet	5.13USD	tablet
Methylprednisolone 32 mg tablet	4.62USD	tablet
Depo-medrol 20 mg/ml vial	3.78USD	ml
Methylprednisolone 16 mg tablet	3.17USD	tablet
Methylprednisolone 40 mg vial	3.0USD	vial
A-methapred 40 mg vial	2.36USD	vial
Medrol 16 mg tablet	2.28USD	tablet
Medrol 8 mg tablet	2.23USD	tablet
Methylprednisolone 8 mg tablet	1.74USD	tablet
Methylprednisolone 4 mg tablet	1.68USD	tablet
Medrol 4 mg dosepak	1.59USD	each
Medrol 4 mg tablet	0.99USD	tablet
Medrol 2 mg tablet	0.84USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	232.5 °C	PhysProp
water solubility	120 mg/L (at 25 °C)	YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP	1.5	Not Available
logS	-2.99	ADME Research, USCD

Predicted Properties

Property	Value	Source
Water Solubility	0.109 mg/mL	ALOGPS
logP	2.06	ALOGPS
logP	1.56	ChemAxon
logS	-3.5	ALOGPS
pKa (Strongest Acidic)	12.58	ChemAxon
pKa (Strongest Basic)	-2.9	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	5	ChemAxon
Hydrogen Donor Count	3	ChemAxon
Polar Surface Area	94.83 Å²	ChemAxon
Rotatable Bond Count	2	ChemAxon
Refractivity	103.04 m³·mol^-1	ChemAxon
Polarizability	40.84 Å³	ChemAxon
Number of Rings	4	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9911
Blood Brain Barrier	+	0.9484
Caco-2 permeable	-	0.6404
P-glycoprotein substrate	Substrate	0.7812
P-glycoprotein inhibitor I	Non-inhibitor	0.7489
P-glycoprotein inhibitor II	Non-inhibitor	0.604
Renal organic cation transporter	Non-inhibitor	0.769
CYP450 2C9 substrate	Non-substrate	0.8415
CYP450 2D6 substrate	Non-substrate	0.9115
CYP450 3A4 substrate	Substrate	0.7582
CYP450 1A2 substrate	Non-inhibitor	0.9473
CYP450 2C9 inhibitor	Non-inhibitor	0.907
CYP450 2D6 inhibitor	Non-inhibitor	0.9513
CYP450 2C19 inhibitor	Non-inhibitor	0.9026
CYP450 3A4 inhibitor	Non-inhibitor	0.8309
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9167
Ames test	Non AMES toxic	0.9337
Carcinogenicity	Non-carcinogens	0.9529
Biodegradation	Not ready biodegradable	0.9492
Rat acute toxicity	2.0025 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9459
hERG inhibition (predictor II)	Non-inhibitor	0.5985

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-0a6r-0019000000-3a4955cf7cc34e1e8d0f
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-0k9i-0696000000-003c4527b983cf71aefd
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-01p9-0980000000-e5097669b38e84057a0f
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-01p9-0960000000-ef914702163187cc80af
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-06y9-0940000000-54b01b6c04c68be3f1b3
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-0009000000-3fe2869617af3697e2ed
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-0009000000-8ad4f169606968256614
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0f79-0895000000-29d1cbf49bb2b32c5a98
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-01p9-0940000000-baa402ac94c228229ea2
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-01p9-0910000000-5cf9fb219d798a9316f4
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4r-0910000000-a2d2af7f573229dc3147
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0006-2900000000-a01d5bfe926dc48e6e4c
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-0019000000-11519ee9583104c00505
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0gw0-0974000000-af5d4ebce055ce6efb23
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-01p9-0960000000-22e2342fcec2bf1cd833
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-01p9-0920000000-63759535c53af1efb13f
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0c09-1900000000-a48c07db31cf27cf0381
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-05tp-2900000000-b802f5e17b69cd6c707f
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0a4i-0009000000-0e0cc8bfc7721357c5cf
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0bti-0896000000-86854a3fa2cb3c3bde0b
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0a4r-0796000000-b0070da713077c3f7975
MS/MS Spectrum - , positive	LC-MS/MS	splash10-01p9-3950000000-b938f656c358e1e42bb5

Taxonomy

Description: This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom: Organic compounds
Super Class: Lipids and lipid-like molecules
Class: Steroids and steroid derivatives
Sub Class: Hydroxysteroids
Direct Parent: 21-hydroxysteroids
Alternative Parents: Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 3-oxo delta-1,4-steroids / 17-hydroxysteroids / 11-beta-hydroxysteroids / Delta-1,4-steroids / Tertiary alcohols / Alpha-hydroxy ketones / Secondary alcohols / Cyclic ketones
show 4 more
Substituents: Progestogin-skeleton / 21-hydroxysteroid / 20-oxosteroid / Pregnane-skeleton / 3-oxo-delta-1,4-steroid / 3-oxosteroid / Oxosteroid / 11-beta-hydroxysteroid / 11-hydroxysteroid / 17-hydroxysteroid
show 15 more
Molecular Framework: Aliphatic homopolycyclic compounds
External Descriptors: 6-methylprednisolone (CHEBI:6888) / C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives (LMST02030178)

Targets

Details1. Glucocorticoid receptor

Kind: Protein
Organism: Human
Pharmacological action: Yes
Actions: Agonist

General Function: Zinc ion binding
Specific Function: Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name: NR3C1
Uniprot ID: P04150
Uniprot Name: Glucocorticoid receptor
Molecular Weight: 85658.57 Da

References

Owen HC, Miner JN, Ahmed SF, Farquharson C: The growth plate sparing effects of the selective glucocorticoid receptor modulator, AL-438. Mol Cell Endocrinol. 2007 Jan 29;264(1-2):164-70. Epub 2006 Dec 19. [PubMed:17182172]
Juruena MF, Cleare AJ, Papadopoulos AS, Poon L, Lightman S, Pariante CM: Different responses to dexamethasone and prednisolone in the same depressed patients. Psychopharmacology (Berl). 2006 Dec;189(2):225-35. Epub 2006 Oct 3. [PubMed:17016711]
Boivin MA, Ye D, Kennedy JC, Al-Sadi R, Shepela C, Ma TY: Mechanism of glucocorticoid regulation of the intestinal tight junction barrier. Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G590-8. Epub 2006 Oct 26. [PubMed:17068119]
Quesnell RR, Han X, Schultz BD: Glucocorticoids stimulate ENaC upregulation in bovine mammary epithelium. Am J Physiol Cell Physiol. 2007 May;292(5):C1739-45. Epub 2007 Jan 24. [PubMed:17251323]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Details1. Cytochrome P450 3A4

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate
Inhibitor

General Function: Vitamin d3 25-hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name: CYP3A4
Uniprot ID: P08684
Uniprot Name: Cytochrome P450 3A4
Molecular Weight: 57342.67 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Details1. Multidrug resistance protein 1

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Xenobiotic-transporting atpase activity
Specific Function: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name: ABCB1
Uniprot ID: P08183
Uniprot Name: Multidrug resistance protein 1
Molecular Weight: 141477.255 Da

References

Oka A, Oda M, Saitoh H, Nakayama A, Takada M, Aungst BJ: Secretory transport of methylprednisolone possibly mediated by P-glycoprotein in Caco-2 cells. Biol Pharm Bull. 2002 Mar;25(3):393-6. [PubMed:11913542]
Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019]
Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [PubMed:14661924]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 19:27

Methylprednisolone

Identification

Structure for DB00959 (Methylprednisolone)

Pharmacology

Interactions

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Taxonomy

Targets

References

Enzymes

References

Transporters

References